



(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 16/28 (2006.01)

A61P 35/00 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2017/030156

(22) International Filing Date:

28 April 2017 (28.04.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/329,729 29 April 2016 (29.04.2016) US

62/460,371 17 February 2017 (17.02.2017) US

(71) Applicant: AVEO PHARMACEUTICALS, INC.

[US/US]; One Broadway, 14th Floor, Cambridge, MA 02142 (US).

(72) Inventors: OKAMURA, Heidi; 19 Mason Terrace, Brook-

line, MA 02446 (US). WINSTON, William, M., Jr.;

100 Spoonhill Avenue, Marlborough, MA 01752 (US).

POLING, Laura; 1365 Boylston Street, Apartment 546,

Boston, MA 02215 (US). BELL, Alisa, C.; 6 Page Road,

Bedford, MA 01730 (US).

(74) Agent: KOMM, Crystal, A. et al.; Goodwin Procter LLP,

100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-NOTCH3 ANTIBODY

(57) Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.



WO 2017/190025 A1

ANTI-NOTCH3 ANTIBODY

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62/460,371 filed February 17, 2017, and U.S. Provisional Application No. 62/329,729, filed April 29, 2016, the contents of each of which are incorporated by reference herein in their entirety.

FIELD OF THE INVENTION

[0002] The field of the invention is molecular biology, specifically immunology and antibodies that bind human Notch3.

BACKGROUND

[0003] Notch pathway signaling is involved in numerous cellular processes, including cell fate determination, differentiation, proliferation, apoptosis, migration and angiogenesis. In mammals, there are four Notch proteins (sometimes called “Notch receptors”), designated Notch1-Notch4. All four Notch proteins have a similar domain structure, which includes an extracellular domain, a negative regulatory (NRR) domain, a single-pass transmembrane domain, and an intracellular domain. The extracellular domain contains a series of EGF-like repeats that are involved in ligand binding. During maturation, the Notch polypeptide is cleaved by a furin-like protease. This cleavage divides the Notch protein into two subunits that are held together by the NRR. In the absence of ligand binding, the NRR domain functions to keep the Notch protein in a protease-resistant conformation. The intracellular domain is a transcription factor called Notch intracellular domain (NICD), which is released upon proteolytic cleavage by gamma secretase, in response to binding of the Notch protein by a ligand. In mammals, the Notch ligands are Delta-like (*e.g.*, DLL1 and DLL4) and Jagged (also referred to as Jag, *e.g.*, Jag1 and Jag2). When the NICD is released, it travels to the nucleus, where it activates transcription of the Notch-responsive genes, HES1, HES5, NRARP, Deltex1 and c-MYC. For reviews of Notch-related biology, see, *e.g.*, Bray, 2006, NATURE REVIEWS 7:678-689; Kopan *et al.*, 2009, CELL 137:216-233.

[0004] While Notch proteins play crucial roles in normal development, dysregulation of the Notch proteins is associated with various types of cancer, including T-cell acute lymphatic leukemia/lymphoma (T-ALL), breast cancer, colon cancer, ovarian cancer and lung cancer. See, *e.g.*, Miele *et al.*, 2006, CURRENT CANCER DRUG TARGETS 6:313-323. Accordingly, one therapeutic approach for the treatment of cancer is inhibition of Notch pathway signaling. Inhibition of Notch pathway signaling has been achieved using monoclonal antibodies (Wu *et al.*, 2010, NATURE 464:1052-1057; Aste-Amézaga *et al.*, 2010, PLOS ONE 5:1-13 e9094). Further, dysregulation of Notch may be associated with development of pulmonary arterial hypertension (PAH). Accordingly, a therapeutic approach to treating PAH may involve inhibition of the Notch pathway signaling. (Li *et al.*, 2009, Nature Medicine, 15:1289-1299; Jalali *et al.*, 2012, PLOS ONE 7:e46808; Yu *et al.*, 2013, Am. J. Respir. Cell Mol. Biol., 48:647-654; Chida *et al.*, 2014, Mol Gen. & Gen. Med., 2:229-239.)

[0005] Naturally-occurring antibodies are multimeric proteins that contain four polypeptide chains (**FIG. 1**). Two of the polypeptide chains are called immunoglobulin heavy chains (H chains), and two of the polypeptide chains are called immunoglobulin light chains (L chains). The immunoglobulin heavy and light chains are connected by an interchain disulfide bond. The immunoglobulin heavy chains are connected by interchain disulfide bonds. A light chain consists of one variable region (V_L in **FIG. 1**) and one constant region (C_L in **FIG. 1**). The heavy chain consists of one variable region (V_H in **FIG. 1**) and at least three constant regions (CH_1 , CH_2 and CH_3 in **FIG. 1**). The variable regions determine the specificity of the antibody.

[0006] Each variable region contains three hypervariable regions known as complementarity determining regions (CDRs) flanked by four relatively conserved regions known as framework regions (FRs). The three CDRs, referred to as CDR₁, CDR₂, and CDR₃, contribute to the antibody binding specificity. Naturally occurring antibodies have been used as starting material for engineered antibodies, such as chimeric antibodies and humanized antibodies.

[0007] There is a need for improved antibodies that neutralize the biological activity of human Notch3 and that can be used as therapeutic agents to treat human patients.

SUMMARY OF THE INVENTION

[0008] The invention is based, in part, upon the discovery of antibodies that specifically bind human Notch3. Antibodies disclosed herein contain human Notch3 binding sites based on

the CDRs of the anti-Notch3 antibodies described herein. The antibodies can be used as therapeutic agents, and, depending upon the intended uses, can be optimized, *e.g.*, affinity-matured, to improve biochemical properties (*e.g.*, affinity and/or specificity), to improve biophysical properties (*e.g.*, aggregation, stability, precipitation, and/or non-specific interactions), and/or to reduce or eliminate immunogenicity, when administered to a human subject.

[0009] The disclosed antibodies prevent or inhibit activation of human Notch3, which they do by inhibiting Notch3 from binding to Notch ligands, *i.e.*, Jag1, Jag2, DLL1, and DLL4. The disclosed antibodies can be used to inhibit the proliferation of tumor cells *in vitro* and/or *in vivo*. When administered to a human subject with cancer, the antibodies inhibit or reduce tumor growth in the subject. When administered to a human with pulmonary arterial hypertension (PAH), the antibodies treat, reduce, or alleviate the symptoms and/or causes of PAH.

[0010] These and other aspects and advantages of the invention are illustrated by the following figures, detailed description and claims.

DESCRIPTION OF THE DRAWINGS

[0011] The invention can be more completely understood with reference to the following drawings.

[0012] **FIG. 1** is a schematic representation of a typical, naturally-occurring antibody.

[0013] **FIG. 2** provides the amino acid sequence corresponding to the extracellular domain (ECD; amino acids 40 to 1643) of human Notch3 (SEQ ID NO:19).

[0014] **FIG. 3** provides the amino acid sequence corresponding to EGF-like repeats 1-11 (amino acids 40 to 467 of the extracellular domain shown in **FIG.2**) of human Notch3 (SEQ ID NO:20).

[0015] **FIG. 4** shows the amino acid sequence for the complete heavy chain variable region (SEQ ID NO:6) of antibody 28042. Sequences corresponding to CDR₁ (SEQ ID NO:3), CDR₂ (SEQ ID NO:4), and CDR₃ (SEQ ID NO:5) are identified in boxes. The unboxed sequences represent framework (FR) sequences.

[0016] **FIG. 5** shows the amino acid sequence for the complete light (kappa) chain variable region (SEQ ID NO:10) of antibody 28042. Sequences corresponding to CDR₁ (SEQ ID NO:7), CDR₂ (SEQ ID NO:8), and CDR₃ (SEQ ID NO:9) are identified in boxes. The unboxed sequences represent framework (FR) sequences.

5 [0017] **FIG. 6** shows the binding of the 28042 antibody to Fc fusion proteins of the extracellular domains of Notch1, Notch2, and Notch3, as observed by surface plasmon resonance (SPR). Binding was measured at three different dilutions. The results demonstrate that the binding affinity of the 28042 antibody for Notch3 is high while there is no appreciable binding of the 28042 antibody to Notch1 or Notch2.

10 [0018] **FIG. 7** shows the binding of the 28042 antibody to cell surface human Notch1, human Notch2, human Notch3, and murine Notch3 as observed by FACS. The results demonstrate that the 28042 antibody binds human and murine Notch3 while there is no appreciable binding of the 28042 antibody to Notch1 or Notch2.

[0019] **FIG. 8** is a Western blot that shows the level of inhibition of Jag1-induced Notch3 activation by the 28042 antibody as compared to other antibodies, as assessed by extent of intracellular domain cleavage of mNotch3 expressed in FlpInTM cells.

[0020] **FIG. 9** is a Western blot that shows the level of inhibition of DLL4-induced human Notch3 receptor activation, as assessed by Notch3 intracellular domain cleavage in NCI-H838 cells plated on ligand in the presence of the 28042 antibody and other antibodies.

20 [0021] **FIGS. 10A-B** show the inhibition of ligand-induced Notch3 receptor activation, as assayed by Notch3 intracellular domain cleavage. **FIG. 10A** is a Western blot that shows the level of inhibition of Jag1, Jag2, and DLL4 induced Notch3 activation by the 28042 antibody as assessed by extent of intracellular domain cleavage of murine Notch3 expressed in FlpInTM cells. **FIG. 10B** is a Western blot that shows the level of inhibition of Jag1, Jag2, and DLL4 induced Notch3 activation by the 28042 antibody as assessed by extent of intracellular domain cleavage of human Notch3 expressed in FlpInTM cells.

25 [0022] **FIG. 11** is a dose-response curve based on a human Notch3 reporter assay showing that the 28042 antibody inhibits functional Notch3 activation, as measured by Notch3-dependent reporter gene expression in the presence of the Fc-bound ligand Jag2 (Jag2-Fc). The graph shows the inhibition of Jag2-Fc-stimulated reporter activity (% Inhibition) by antibody

the 28042 antibody in stably transduced cells as a function of the amount of the 28042 antibody.

[0023] **FIGS. 12A-B** show the inhibition of tumor growth by the 28042 antibody in a Notch3-mediated mouse tumor model. **FIG. 12A** shows the tumor volume over time (in days) for mice treated with hIgG or the 28042 antibody. The 28042 antibody showed significant tumor growth inhibition compared to the IgG control. **FIG. 12B** depicts results of Western blotting performed on lysate of harvested tumors using an antibody specific for the Notch3 C-terminus in order to detect the extent of Notch intracellular domain cleavage. β -tubulin was used as a loading control.

10 [0024] **FIG. 13** shows an alignment of the light chain variable region amino acid sequences for the 28042 antibody and variants 28042.1-28042.10. CDRs are identified by bold lettering and boxes.

[0025] **FIG. 14** shows the light chain CDRs for the 28042 antibody and variants 28042.1-28042.10.

DETAILED DESCRIPTION

15 [0026] The antibodies disclosed herein are based on the antigen binding sites of certain monoclonal antibodies that have been selected on the basis of binding and neutralizing the activity of human Notch3. The antibodies contain immunoglobulin variable region CDR sequences that define a binding site for human Notch3.

[0027] Because of the neutralizing activity of these antibodies, they can be used to inhibit the growth and/or proliferation of certain cancer cells and tumors and for treating pulmonary arterial hypertension (PAH) or other conditions where the Notch3 pathway is involved. When used as a therapeutic agent, the antibodies can be optimized, *e.g.*, affinity-matured, to improve biochemical properties and/or biophysical properties, and/or to reduce or eliminate immunogenicity when administered to a human patient. Various features and aspects of the invention are discussed in more detail below.

20 [0028] As used herein, unless otherwise indicated, the term “antibody” means an intact antibody (*e.g.*, an intact monoclonal antibody) or antigen-binding fragment of an antibody, including an intact antibody or antigen-binding fragment that has been modified, engineered or chemically conjugated. Examples of antibodies that have been modified or engineered are

chimeric antibodies, humanized antibodies, and multispecific antibodies (*e.g.*, bispecific antibodies). Examples of antigen-binding fragments include Fab, Fab', F(ab')₂, Fv, single chain antibodies (*e.g.*, scFv), minibodies, and diabodies. An antibody conjugated to a toxin moiety is an example of a chemically conjugated antibody.

I. Antibodies that Bind Human Notch3

[0029] As disclosed herein, the antibodies may comprise: (a) an immunoglobulin heavy chain variable region comprising the structure CDR_{H1}-CDR_{H2}-CDR_{H3} and (b) an immunoglobulin light chain variable region comprising the structure CDR_{L1}-CDR_{L2}-CDR_{L3},
5 wherein the heavy chain variable region and the light chain variable region together define a single binding site for binding human Notch3.

[0030] In some embodiments, the antibody comprises: (a) an immunoglobulin heavy chain variable region comprising the structure CDR_{H1}-CDR_{H2}-CDR_{H3} and (b) an immunoglobulin light chain variable region, wherein the heavy chain variable region and the light chain variable
10 region together define a single binding site for binding hNotch3. A CDR_{H1} comprises the amino acid sequence of SEQ ID NO: 3; a CDR_{H2} comprises the amino acid sequence of SEQ ID NO: 4 and a CDR_{H3} comprises the amino acid sequence of SEQ ID NO: 5. The CDR_{H1}, CDR_{H2}, and CDR_{H3} sequences are interposed between immunoglobulin FR sequences.

[0031] In some embodiments, the antibody comprises (a) an immunoglobulin light chain variable region comprising the structure CDR_{L1}-CDR_{L2}-CDR_{L3}, and (b) an immunoglobulin heavy chain variable region, wherein the IgG light chain variable region and the IgG heavy chain variable region together define a single binding site for binding hNotch3. A CDR_{L1} comprises the amino acid sequence of SEQ ID NO: 7, a CDR_{L2} comprises the amino acid sequence of SEQ ID NO: 8; and a CDR_{L3} comprises the amino acid sequence of SEQ ID NO:
15 9. The CDR_{L1}, CDR_{L2}, and CDR_{L3} sequences are interposed between immunoglobulin FR sequences.

[0032] In some embodiments, the antibody comprises (a) an immunoglobulin light chain variable region comprising the structure CDR_{L1}-CDR_{L2}-CDR_{L3}, and (b) an immunoglobulin heavy chain variable region, wherein the IgG light chain variable region and the IgG heavy chain variable region together define a single binding site for binding hNotch3. A CDR_{L1}
20 25

comprises the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO:21, a CDR_{L2} comprises the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 22; and a CDR_{L3} comprises the amino acid sequence of SEQ ID NO: 9. The CDR_{L1}, CDR_{L2}, and CDR_{L3} sequences are interposed between immunoglobulin FR sequences.

5 [0033] In some embodiments, the antibody comprises: (a) an immunoglobulin heavy chain variable region comprising the structure CDR_{H1}-CDR_{H2}-CDR_{H3} and (b) an immunoglobulin light chain variable region comprising the structure CDR_{L1}-CDR_{L2}-CDR_{L3}, wherein the heavy chain variable region and the light chain variable region together define a single binding site for binding hNotch3. The CDR_{H1} is the amino acid sequence of SEQ ID NO: 3; the CDR_{H2} is the amino acid sequence of SEQ ID NO: 4 ; and the CDR_{H3} is the amino acid sequence of SEQ ID NO: 5 . The CDR_{L1} is the amino acid sequence of SEQ ID NO: 7 ; the CDR_{L2} is the amino acid sequence of SEQ ID NO: 8 ; and the CDR_{L3} is the amino acid sequence of SEQ ID NO: 9.

[0034] In some embodiments, the antibody comprises: (a) an immunoglobulin heavy chain variable region comprising the structure CDR_{H1}-CDR_{H2}-CDR_{H3} and (b) an immunoglobulin light chain variable region comprising the structure CDR_{L1}-CDR_{L2}-CDR_{L3}, wherein the heavy chain variable region and the light chain variable region together define a single binding site for binding hNotch3. The CDR_{H1} is the amino acid sequence of SEQ ID NO: 3; the CDR_{H2} is the amino acid sequence of SEQ ID NO: 4 ; and the CDR_{H3} is the amino acid sequence of SEQ ID NO: 5 . The CDR_{L1} is the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 21 ; the CDR_{L2} is the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 22; and the CDR_{L3} is the amino acid sequence of SEQ ID NO: 9.

[0035] In other embodiments, the antibodies disclosed herein comprise an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region. In some embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 6, and an immunoglobulin light chain variable region.

[0036] In other embodiments, the antibody comprises an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 10 and an immunoglobulin heavy chain variable region.

30 [0037] In other embodiments, the antibody comprises an immunoglobulin light chain variable region comprising the amino acid sequence selected from the group consisting of SEQ

ID NO: 10, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39 and an immunoglobulin heavy chain variable region.

5 [0038] In some embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 6, and an immunoglobulin light chain variable region comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39.

10 [0039] In some embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 6, and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 10.

15 [0040] In some embodiments, the antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 6, and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 10, wherein the amino acid sequence of SEQ ID NO: 10 includes a mutation at one or more of positions 31, 50, 62, 65, 106, and 107. In some embodiments, the amino acid sequence of SEQ ID NO: 10 includes one or more mutations selected from the group consisting of N31S, G50A, V62F, T65S F106I, and E107K.

20 [0041] In certain embodiments, the antibodies disclosed herein comprise an immunoglobulin heavy chain and an immunoglobulin light chain. In some embodiments, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 1, and an immunoglobulin light chain.

25 [0042] In other embodiments, the antibody comprises an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 2, and an immunoglobulin heavy chain.

[0043] In other embodiments, the antibody comprises an immunoglobulin light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42 and an
30 immunoglobulin heavy chain.

[0044] In some embodiments, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 1, and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 2.

5 [0045] In some embodiments, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 1, and an immunoglobulin light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42.

10 [0046] In some embodiments, the antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 1, and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 2, wherein the amino acid sequence of SEQ ID NO: 2 includes a mutation at one or more of positions 31, 50, 62, 65, 106, and 107. In some embodiments, the amino acid sequence of SEQ ID NO: 10 includes one or more mutations selected from the group consisting of N31S, G50A, V62F, T65S, F106I, and E107K.

15 [0047] In certain embodiments, an isolated antibody that binds hNotch3 comprises an immunoglobulin heavy chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the entire variable region or the framework region sequence of SEQ ID NO: 6. In certain embodiments, an isolated antibody that binds hNotch3 comprises an immunoglobulin light chain variable region
20 comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the entire variable region or the framework region sequence of SEQ ID NO: 10. In certain embodiments, an isolated antibody that binds hNotch3 comprises an immunoglobulin light chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the entire variable
25 region or the framework region sequence of SEQ ID NO: 23, 24, 25, 26, 27, 28, 29, 37, 38, or 39.

[0048] Sequence identity may be determined in various ways that are within the skill in the art, e.g., using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. BLAST (Basic Local Alignment Search Tool) analysis using
30 the algorithm employed by the programs blastp, blastn, blastx, tblastn and tblastx (Karlin *et al.*, (1990) PROC. NATL. ACAD. SCI. USA 87:2264-2268; Altschul, (1993) J. MOL. EVOL. 36, 290-

300; Altschul *et al.*, (1997) NUCLEIC ACIDS RES. 25:3389-3402, incorporated by reference) are tailored for sequence similarity searching. For a discussion of basic issues in searching sequence databases see Altschul *et al.*, (1994) NATURE GENETICS 6:119-129, which is fully incorporated by reference. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. The search parameters for histogram, descriptions, alignments, expect (*i.e.*, the statistical significance threshold for reporting matches against database sequences), cutoff, matrix and filter are at the default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff *et al.*, (1992) PROC. NATL. ACAD. SCI. USA 89:10915-10919, fully incorporated by reference). Four blastn parameters may be adjusted as follows: Q=10 (gap creation penalty); R=10 (gap extension penalty); wink=1 (generates word hits at every wink.sup.th position along the query); and gapw=16 (sets the window width within which gapped alignments are generated). The equivalent Blastp parameter settings may be Q=9; R=2; wink=1; and gapw=32. Searches may also be conducted using the NCBI (National Center for Biotechnology Information) BLAST Advanced Option parameter (e.g.: -G, Cost to open gap [Integer]: default = 5 for nucleotides/ 11 for proteins; -E, Cost to extend gap [Integer]: default = 2 for nucleotides/ 1 for proteins; -q, Penalty for nucleotide mismatch [Integer]: default = -3; -r, reward for nucleotide match [Integer]: default = 1; -e, expect value [Real]: default = 10; -W, wordsize [Integer]: default = 11 for nucleotides/ 28 for megablast/ 3 for proteins; -y, Dropoff (X) for blast extensions in bits: default = 20 for blastn/ 7 for others; -X, X dropoff value for gapped alignment (in bits): default = 15 for all programs, not applicable to blastn; and -Z, final X dropoff value for gapped alignment (in bits): 50 for blastn, 25 for others). ClustalW for pairwise protein alignments may also be used (default parameters may include, *e.g.*, Blosum62 matrix and Gap Opening Penalty = 10 and Gap Extension Penalty = 0.1). A Bestfit comparison between sequences, available in the GCG package version 10.0, uses DNA parameters GAP=50 (gap creation penalty) and LEN=3 (gap extension penalty) and the equivalent settings in protein comparisons are GAP=8 and LEN=2.

[0049] In each of the foregoing embodiments, it is contemplated herein that immunoglobulin heavy chain variable region sequences and/or light chain variable region sequences that together bind hNotch3 may contain amino acid alterations (*e.g.*, at least 1, 2, 3,

4, 5, or 10 amino acid substitutions, deletions, or additions) in the framework regions of the heavy and/or light chain variable regions.

[0050] In certain embodiments, the antibody binds hNotch3 with a K_D of 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM or lower. Unless otherwise
5 specified, K_D values are determined by surface plasmon resonance or bio-layer interferometry methods under the conditions described in Example 2.

[0051] In some embodiments, monoclonal antibodies bind to the same epitope on hNotch3 as that bound by the 28042 antibody. In some embodiments, monoclonal antibodies compete for binding to hNotch3 with the 28042 antibody. For example, monoclonal antibodies may
10 compete for binding to the extracellular domain (ECD) of Notch3 with the 28042 antibody. In another example, monoclonal antibodies may compete for binding to EGF-like repeats 1-11 of human Notch3 with the 28042 antibody (amino acid sequence corresponding to EGF-like repeats 1-11 of human Notch3 is shown in **FIG. 3**).

[0052] Competition assays for determining whether an antibody binds to the same epitope as, or competes for binding with, the 28042 antibody are known in the art. Exemplary
15 competition assays include immunoassays (*e.g.*, ELISA assays, RIA assays), BIAcore analysis, biolayer interferometry, and flow cytometry.

[0053] Typically, a competition assay involves the use of an antigen (*e.g.*, a human Notch3 protein or fragment thereof) bound to a solid surface or expressed on a cell surface, a test
20 Notch3-binding antibody and a reference antibody (*e.g.*, the 28042 antibody). The reference antibody is labeled and the test antibody is unlabeled. Competitive inhibition is measured by determining the amount of labeled reference antibody bound to the solid surface or cells in the presence of the test antibody. Usually the test antibody is present in excess (*e.g.*, 1x, 5x, 10x, 20x or 100x). Antibodies identified by competition assay (*i.e.*, competing antibodies) include
25 antibodies binding to the same epitope, or similar (*e.g.*, overlapping) epitopes, as the reference antibody, and antibodies binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur.

[0054] In an exemplary competition assay, a reference Notch3 antibody (*e.g.*, the 28042 antibody) is biotinylated using commercially available reagents. The biotinylated reference
30 antibody is mixed with serial dilutions of the test antibody or unlabeled reference antibody (self-competition control) resulting in a mixture of various molar ratios (*e.g.*, 1x, 5x, 10x, 20x

or 100x) of test antibody (or unlabeled reference antibody) to labeled reference antibody. The antibody mixture is added to a human Notch3 (*e.g.*, extracellular domain of human Notch3) polypeptide coated-ELISA plate. The plate then is washed and HRP (horseradish peroxidase)-streptavidin is added to the plate as the detection reagent. The amount of labeled reference

antibody bound to the target antigen is detected following addition of a chromogenic substrate (*e.g.*, TMB (3,3',5,5'-tetramethylbenzidine) or ABTS (2,2'-azino-di-(3-ethylbenzthiazoline-6-sulfonate)), which are well-known in the art. Optical density readings (OD units) are measured using a SpectraMax M2 spectrometer (Molecular Devices). OD units corresponding to zero percent inhibition are determined from wells without any competing antibody. OD units

corresponding to 100% inhibition, *i.e.*, the assay background are determined from wells without any labeled reference antibody or test antibody. Percent inhibition of labeled reference antibody to Notch3 by the test antibody (or the unlabeled reference antibody) at each concentration is calculated as follows: % inhibition = $(1 - (\text{OD units} - 100\% \text{ inhibition}) / (0\% \text{ inhibition} - 100\% \text{ inhibition})) * 100$. Persons skilled in the art will appreciate that the

competition assay can be performed using various detection systems well-known in the art.

[0055] A competition assay can be conducted in both directions to ensure that the presence of the label does not interfere or otherwise inhibit binding. For example, in the first direction the reference antibody is labeled and the test antibody is unlabeled, and in the second direction, the test antibody is labeled and the reference antibody is unlabeled.

[0056] A test antibody competes with the reference antibody for specific binding to the antigen if an excess of one antibody (*e.g.*, 1x, 5x, 10x, 20x or 100x) inhibits binding of the other antibody, *e.g.*, by at least 50%, 75%, 90%, 95% or 99% as measured in a competitive binding assay.

[0057] Two antibodies may be determined to bind to the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other. Two antibodies may be determined to bind to overlapping epitopes if only a subset of the amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.

II. Antibody Production

[0058] Methods for producing antibodies of the invention are known in the art. For example, DNA molecules encoding light chain variable regions and/or heavy chain variable regions can be chemically synthesized using the sequence information provided herein.

5 Synthetic DNA molecules can be ligated to other appropriate nucleotide sequences, including, *e.g.*, constant region coding sequences, and expression control sequences, to produce conventional gene expression constructs encoding the desired antibody. Production of defined gene constructs is within routine skill in the art.

[0059] Nucleic acids encoding desired antibodies can be incorporated (ligated) into
10 expression vectors, which can be introduced into host cells through conventional transfection or transformation techniques. Exemplary host cells are *E. coli* cells, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (*e.g.*, Hep G2), and myeloma cells that do not otherwise produce IgG protein. Transformed host cells can be grown under conditions that permit the
15 host cells to express the genes that encode the immunoglobulin light and/or heavy chain variable regions.

[0060] Specific expression and purification conditions will vary depending upon the expression system employed. For example, if a gene is to be expressed in *E. coli*, it is first cloned into an expression vector by positioning the engineered gene downstream from a
20 suitable bacterial promoter, *e.g.*, Trp or Tac, and a prokaryotic signal sequence. The expressed secreted protein accumulates in refractile or inclusion bodies, and can be harvested after disruption of the cells by French press or sonication. The refractile bodies then are solubilized, and the proteins refolded and cleaved by methods known in the art.

[0061] If the engineered gene is to be expressed in eukaryotic host cells, *e.g.*, CHO cells, it
25 is first inserted into an expression vector containing a suitable eukaryotic promoter, a secretion signal, a poly A sequence, and a stop codon, and, optionally, may contain enhancers, and various introns. This expression vector optionally contains sequences encoding all or part of a constant region, enabling an entire, or a part of, a heavy or light chain to be expressed. The gene construct can be introduced into eukaryotic host cells using conventional techniques. The
30 host cells express V_L or V_H fragments, V_L-V_H heterodimers, V_H-V_L or V_L-V_H single chain polypeptides, complete heavy or light immunoglobulin chains, or portions thereof, each of

which may be attached to a moiety having another function (*e.g.*, cytotoxicity). In some embodiments, a host cell is transfected with a single vector expressing a polypeptide expressing an entire, or part of, a heavy chain (*e.g.*, a heavy chain variable region) or a light chain (*e.g.*, a light chain variable region). In other embodiments, a host cell is transfected with a single
5 vector encoding (a) a polypeptide comprising a heavy chain variable region and a polypeptide comprising a light chain variable region, or (b) an entire immunoglobulin heavy chain and an entire immunoglobulin light chain. In still other embodiments, a host cell is co-transfected with more than one expression vector (*e.g.*, one expression vector encoding a polypeptide comprising an entire, or part of, a heavy chain or heavy chain variable region, and another
10 expression vector encoding a polypeptide comprising an entire, or part of, a light chain or light chain variable region).

[0062] A polypeptide comprising an immunoglobulin heavy chain variable region or light chain variable region can be produced by growing (culturing) a host cell transfected with an expression vector encoding such variable region, under conditions that permit expression of the
15 polypeptide. Following expression, the polypeptide can be harvested and purified or isolated using techniques known in the art, *e.g.*, affinity tags such as glutathione-S-transferase (GST) and histidine tags.

[0063] A monoclonal antibody that binds human Notch3, or an antigen-binding fragment of the antibody, can be produced by growing (culturing) a host cell transfected with: (a) an
20 expression vector that encodes a complete or partial immunoglobulin heavy chain, and a separate expression vector that encodes a complete or partial immunoglobulin light chain; or (b) a single expression vector that encodes both chains (*e.g.*, complete or partial heavy and light chains), under conditions that permit expression of both chains. The intact antibody (or antigen-binding fragment of the antibody) can be harvested and purified or isolated using
25 techniques known in the art, *e.g.*, Protein A, Protein G, affinity tags such as glutathione-S-transferase (GST) and histidine tags. It is within ordinary skill in the art to express the heavy chain and the light chain from a single expression vector or from two separate expression vectors.

III. Antibody Modifications

[0064] Human monoclonal antibodies can be isolated or selected from phage display
30 libraries including immune, naïve and synthetic libraries. Antibody phage display libraries are

known in the art, *see, e.g.*, Hoet *et al.*, NATURE BIOTECH. 23:344-348, 2005; Soderlind *et al.*, NATURE BIOTECH. 18:852-856, 2000; Rothe *et al.*, J. MOL. BIOL. 376:1182-1200, 2008; Knappik *et al.*, J. MOL. BIOL. 296:57-86, 2000; and Krebs *et al.*, J. IMMUNOL. METH. 254:67-84, 2001. When used as a therapeutic, human antibodies isolated by phage display may be
5 optimized (*e.g.*, affinity-matured) to improve biochemical characteristics including affinity and/or specificity, improve biophysical properties including aggregation, stability, precipitation and/or non-specific interactions, and/or to reduce immunogenicity. Affinity-maturation procedures are within ordinary skill in the art. For example, diversity can be introduced into an immunoglobulin heavy chain and/or an immunoglobulin light chain by DNA shuffling, chain
10 shuffling, CDR shuffling, random mutagenesis and/or site-specific mutagenesis.

[0065] In some embodiments, isolated human antibodies contain one or more somatic mutations. In these cases, antibodies can be modified to a human germline sequence to optimize the antibody (*i.e.*, a process referred to as germlining).

[0066] Generally, an optimized antibody has at least the same, or substantially the same,
15 affinity for the antigen as the non-optimized (or parental) antibody from which it was derived. Preferably, an optimized antibody has a higher affinity for the antigen when compared to the parental antibody.

[0067] Human antibody fragments (*e.g.*, parental and optimized variants) can be engineered to contain certain constant (*i.e.*, Fc) regions with a specified effector function (*e.g.*, antibody-
20 dependent cellular cytotoxicity (ADCC)). Human constant regions are known in the art.

[0068] If the antibody is for use as a therapeutic, it can be conjugated to an effector agent such as a small molecule toxin or a radionuclide using standard *in vitro* conjugation chemistries. If the effector agent is a polypeptide, the antibody can be chemically conjugated to the effector or joined to the effector as a fusion protein. Construction of fusion proteins is
25 within ordinary skill in the art.

[0069] The antibody can be conjugated to an effector moiety such as a small molecule toxin or a radionuclide using standard *in vitro* conjugation chemistries. If the effector moiety is a polypeptide, the antibody can be chemically conjugated to the effector or joined to the effector as a fusion protein. Construction of fusion proteins is within ordinary skill in the art.

IV. Use of Antibodies

[0070] Antibodies disclosed herein can be used to treat various forms of cancer, *e.g.*, leukemia, breast cancer, cervical cancer, colorectal cancer, lung cancer, pancreatic cancer, prostate cancer, gastric cancer, head and neck cancer, endometrial cancer and ovarian cancer.

5 The cancer cells are exposed to a therapeutically effective amount of the antibody so as to inhibit or reduce proliferation of the cancer cells. In some embodiments, the antibodies inhibit cancer cell proliferation by at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or 100% relative to a control antibody that does not bind human Notch3 with the same avidity as the 28042 antibody.

10 [0071] In some embodiments, the 28042 antibody or a variant thereof is used in therapy. For example, the 28042 antibody can be used to inhibit tumor growth in a mammal (*e.g.*, a human patient). In some embodiments, use of the antibody to inhibit tumor growth in a mammal comprises administering to the mammal a therapeutically effective amount of the antibody. In other embodiments, the 28042 antibody or a variant thereof can be used for
15 inhibiting proliferation of a tumor cell. In other embodiments, the 28042 antibody or a variant thereof is used to treat or prevent pulmonary arterial hypertension (PAH).

[0072] In some embodiments, the disclosed antibodies may inhibit or reduce proliferation of a tumor cell by inhibiting binding of human Notch3 to a ligand, *e.g.*, Jag1, Jag2, DLL1, and DLL4. The disclosed antibodies can be used in a method to inhibit tumor growth in a human
20 patient. The method comprises administering to the patient a therapeutically effective amount of the antibody.

[0073] Cancers associated with Notch3 overexpression and/or activation include, but are not limited to, breast cancer, ovarian cancer, prostate cancer, cervical cancer, lung cancer, brain cancer (*e.g.*, glioblastoma, astrocytoma, neuroblastoma), melanomas, gastrointestinal cancers
25 (*e.g.*, colorectal, pancreatic, and gastric), head and neck cancer, sarcomas (*e.g.*, rhabdomyosarcoma, osteosarcoma), and hematopoietic cell cancers, (*e.g.*, multiple myeloma, leukemia, *e.g.*, precursor T acute lymphoblastic leukemia (T-ALL), precursor B acute lymphoblastic leukemia (B-ALL) and B-cell chronic lymphoblastic leukemia (B-CLL)).

[0074] As used herein, “treat”, “treating” and “treatment” mean the treatment of a disease
30 in a mammal, *e.g.*, in a human. This includes: (a) inhibiting the disease, *i.e.*, arresting its development; and (b) relieving the disease, *i.e.*, causing regression of the disease state.

[0075] Generally, a therapeutically effective amount of active component is in the range of 0.1 mg/kg to 100 mg/kg, *e.g.*, 1 mg/kg to 100 mg/kg, 1 mg/kg to 10 mg/kg. The amount administered will depend on variables such as the type and extent of disease or indication to be treated, the overall health of the patient, the *in vivo* potency of the antibody, the pharmaceutical formulation, and the route of administration. The initial dosage can be increased beyond the upper level in order to rapidly achieve the desired blood-level or tissue-level. Alternatively, the initial dosage can be smaller than the optimum, and the daily dosage may be progressively increased during the course of treatment. Human dosage can be optimized, *e.g.*, in a conventional Phase I dose escalation study designed to run from 0.5 mg/kg to 20 mg/kg.

Dosing frequency can vary, depending on factors such as route of administration, dosage amount, serum half-life of the antibody, and the disease being treated. Exemplary dosing frequencies are once per day, once per week and once every two weeks. A preferred route of administration is parenteral, *e.g.*, intravenous infusion. Formulation of monoclonal antibody-based drugs is within ordinary skill in the art. In some embodiments, a monoclonal antibody is lyophilized, and then reconstituted in buffered saline, at the time of administration.

[0076] For therapeutic use, an antibody preferably is combined with a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” means buffers, carriers, and excipients suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. The carrier(s) should be “acceptable” in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient. Pharmaceutically acceptable carriers include buffers, solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art.

[0077] Pharmaceutical compositions containing antibodies disclosed herein can be presented in a dosage unit form and can be prepared by any suitable method. A pharmaceutical composition should be formulated to be compatible with its intended route of administration. Examples of routes of administration are intravenous (IV), intradermal, inhalation, transdermal, topical, transmucosal, and rectal administration. A preferred route of administration for monoclonal antibodies is IV infusion. Useful formulations can be prepared by methods known in the pharmaceutical art. For example, see *Remington's Pharmaceutical Sciences*, 18th ed.

(Mack Publishing Company, 1990). Formulation components suitable for parenteral administration include a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as EDTA; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose.

[0078] For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). The carrier should be stable under the conditions of manufacture and storage, and should be preserved against microorganisms. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof.

[0079] Pharmaceutical formulations preferably are sterile. Sterilization can be accomplished by any suitable method, *e.g.*, filtration through sterile filtration membranes.

Where the composition is lyophilized, filter sterilization can be conducted prior to or following lyophilization and reconstitution.

EXAMPLES

[0080] The following Examples are merely illustrative and are not intended to limit the scope or content of the invention in any way.

Example 1: Anti-Notch3 Antibodies

[0081] This Example describes the production of anti-hNotch3 monoclonal antibodies.

A. Isolation of Anti-Notch3-Antibodies by Phage Display

[0082] Anti-hNotch3 antibodies are isolated from a phage display library constructed from human heavy chain and light chain variable region genes. More specifically, the anti-hNotch3 antibodies are isolated using a phagemid antibody library constructed from human B-cell donor light chain variable and constant genes paired with a single human heavy chain framework consisting of human B-cell donor heavy chain variable region CDR₃ genes and a diversity of synthetic heavy chain variable region CDR₁ and CDR₂ sequences (Dyax Corporation, Burlington, MA).

[0083] An anti-hNotch3 antibody (the 28042 antibody) was isolated from a human antibody phage display library following three phage display selection rounds using diminishing amounts of a biotinylated recombinant concatemer of alternating human and murine Notch 3 EGF-like Repeats 1-11 (FIG. 3) as the antigen. 200 pmol of the antigen was used in round one, followed by 50 and 5 pmol in rounds two and three, respectively. At the start of each round of selection, the phage library was depleted with biotinylated human IgG1 Fc. Each round of selection was followed by infection of TG1 *E. coli* (Agilent Technologies, Santa Clara, CA), rescue with M13K07 helper phage (Life Technologies, Grand Island, NY), and phage amplification to enrich the input for each subsequent round. Colonies resulting from the third round of selection were screened by ELISA for binding to both recombinant human and mouse Notch3. All positive clones were sequenced. Clones with unique sequences were expressed as Fabs, Protein A purified, and screened for function. Functional antibodies were converted to full length IgG1 antibodies and further tested for function.

[0084] Additionally, non-human light chain residues of the 28042 antibody were individually changed to human germline sequences to create additional light chain variants. For example, the 28042.1 antibody contains the light chain CDR mutation N31S; the 28042.2 antibody contains the light chain CDR mutation G50A; the 28042.3 antibody contains the light chain framework mutation F106I; the 28042.4 antibody contains the light chain framework mutation E107K; the 28042.5 antibody contains the light chain CDR and framework mutations N31S and G50A; the 28042.6 antibody contains the light chain framework mutations F106I and E107K; the 28042.7 antibody contains the light chain CDR and framework mutations N31S, G50A, F106I, E107K; the 28042.8 antibody contains the light chain framework mutation V62F; the 28042.9 antibody contains the light chain framework mutation T65S; and the 28042.10 antibody contains the light chain CDR and framework mutations N31S, G50A, V62F, and T65S. An antibody according to the invention may contain 1 or more of the aforementioned light chain framework and/or CDR mutations.

B. Sequences of Anti-Notch3 Antibodies

[0085] The human heavy chains are subcloned into pEE6.4 (Lonza, Basel, Switzerland) via HindIII and EcoRI sites using In-FusionTM PCR cloning (Clontech, Mountain View, CA). The human kappa light chains are subcloned into pEE14.4 (Lonza) via HindIII and EcoRI sites using In-FusionTM PCR cloning.

[0086] Antibody is either expressed by transient transfection of 293T cells with separate heavy and light chain expressing vectors or by stable transfection of CHOK1SV cells (Lonza) with a single vector expressing heavy and light chains. Antibodies are purified for subsequent analysis. A single expression vector can be constructed by combining pEE6.4 and pEE14.4 based vectors. First, pEE6.4 containing full length human heavy chain cDNA is digested with NotI and SalI to create a fragment containing the hCMV-MIE promoter + full length human heavy chain cDNA + SV40 poly A. This fragment is inserted into the pEE14.4 vector already containing full length human light chain cDNA via NotI/SalI sites, thus creating an expression vector that simultaneously expresses heavy and light chains. The combined heavy and light chain vector is linearized and transfected into CHOK1SV cells. Stable clones are selected in the presence of methionine sulfoximine. Binding of the human antibodies to human Notch3 can be measured as described below.

[0087] The nucleic acid sequences encoding and the protein sequences defining variable regions of the human 28042 antibodies are summarized below (amino terminal signal peptide sequences are not shown). In the amino acid sequences, CDR sequences (using the Kabat system) are shown in bold and are underlined.

[0088] Nucleic Acid Sequence Encoding the Heavy Chain of the 28042 Antibody (SEQ ID NO: 11)

```
gaagttcaattgtagagtctggtggcgggtcttggtcagcctggtggttctttacgtctttct
tgcgctgcttccggattcactttctctgattacatgatgtcttgggttcgccaagctcctggt
aaaggtttgagtggtttcttgatccgttcttctggtggcactactctttatgctgactcc
gttaaaggctcgcttcactatctctagagacaactctaagaatactctctacttgcagatgaac
agcttaagggctgaggacacagccacatattactgtgctgagagtcggtggtgggaccacgggt
tatgcttttgatatctggggccaagggacaatggtcaccgtctcaagcgcctcaacaaaagga
ccaagtgtgttcccactcgccctagcagcaagagtacatccgggggactgcagcactcggc
tgccctcgtaaggattattttccagagccagtaaccgtgagctggaacagtggagcactcact
tctggtgtccatacttttctgctgtcctgcaaagctctggcctgtactcactcagctccgtc
gtgaccgtgccatcttcatctctgggcactcagacctacatctgtaatgtaaaccacaagcct
agcaataactaaggctcgataagcgggtggaacccaagagctgcgacaagactcacacttgtccc
ccatgccctgccctgaacttctggggcgggtcccagcgtctttttgttcccaccaaagcctaaa
gatactctgatgataagtagaacacccgaggtgacatgtgttgttagacgtttccacagag
gaccagaggttaagttcaactggtacgttgatggagtcgaagtacataatgctaagaccaag
cctagagaggagcagtataatagtacataccgtgtagtcagtgttctcacagtgtgcaccaa
gactggctcaacggcaaagaatacaaatgcaaagtgtccaacaaagcactcccagcccctatc
gagaagactattagtaaggcaaaggggcagcctcgtgaaccacaggtgtacactctgccaccc
agtagagaggaaatgacaaagaaccaagtctcattgacctgcctggtgaaaggcttctacccc
agcgacatcgccgttgagtgggagagtaacgggtcagcctgagaacaattacaagacaaccccc
```

ccagtgcctggatagtgacgggtctttctttctgtacagtaagctgactgtggacaagtcccgc
 tggcagcagggtaacgtcttcagctgttccgtgatgcacgaggcattgcacaaccactacacc
 cagaagtcactgagcctgagcccagggaag (1353 nucleotides)

[0089] Protein Sequence Defining the Heavy Chain of the 28042 Antibody (SEQ ID NO:

5 1)

Evqllesggglvqpqgslrlscaasgftfs dymmsswvrqapgkglewvs wirssggttlyads
vkgrftisrdnskntlylqmnsdraedtatyycar vgggttgyafdiwgggtmvtvssastkg
 psvfplapsskstsggtaalgclvkdyfpepvtvswngaltsgvhtfpavlgssglyslssv
 10 vtpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpk
 dtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhq
 dwlngkeykckvsnkalpapiektiskakgqprepqvlytlppsreemtknqvsltclvkgyfyp
 sdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhyt
 qkslsispkg (451 amino acids)

15 **[0090] Nucleic Acid Sequence Encoding the Heavy Chain Variable Region of the 28042 Antibody (SEQ ID NO: 17)**

gaagttcaat	tgtagagtc	tggtggcgg	cttggtcagc	ctggtgggtc	50
tttacgtctt	tcttgcgctg	cttccggatt	cactttctct	gattacatga	100
tgtcttgggt	tcgccaagct	cctggtaaag	gtttggagtg	ggtttcttgg	150
20 atccgttctt	ctggtggcac	tactctttat	gctgactccg	ttaaagggtcg	200
cttcactatc	tctagagaca	actctaagaa	tactctctac	ttgcagatga	250
acagcttaag	ggctgaggac	acagccacat	attactgtgc	gagagtcggt	300
ggtgggacca	cgggttatgc	ttttgatata	tggggccaag	ggacaatggt	350
caccgtctca	agc				363

25 **[0091] Protein Sequence Defining the Heavy Chain Variable Region of the 28042 Antibody (SEQ ID NO: 6)**

evqllesggg	lvqpqgslrl	scaasgftfs	<u>dymms</u> swvrqa	pgkglewvs	<u>w</u>	50
<u>irssggttly</u>	<u>adsvkgr</u> fti	srdsnknly	lqmnsdraed	tatyycar	<u>vg</u>	100
<u>ggttgyafdi</u>	wgggtmvtvs	s				121

30 **[0092] Nucleic Acid Sequence Encoding the Kappa Chain of the 28042 Antibody (SEQ ID NO: 12)**

gacatccaga	tgaccagtc	tccatcctcc	ctgtctgcat	ctgtaggaga	50
cagagtcacc	atcacttgcc	gggcaagtca	gagcattagc	aactatttaa	100
attggtatca	gcagaaacca	gggaaagccc	ctaagctcct	gatctatggt	150
35 gcatccagtc	tgcaaagtgg	ggtcccatca	agggtcagtg	gcaactggatc	200
tgggacagat	ttcactctta	ccatcagcag	tctgcaacct	gaagattttg	250

```

caacttacta ctgtcaacag agttacagtc cctcattcac tttcggccct 300
gggaccaaag tggatttcga acgaactgtg gctgcaccat ctgtgttcat 350
ctttccacca agtgatgagc aactgaagtc tggtagctgt tcagtcgtgt 400
gtctgctgaa caatttctac cctcgagaag ccaaagtcca atggaaggta 450
5 gacaacgcac tgcagtccgg caatagccaa gaatcagtta ccgaacagga 500
ttcaaaggac agtacatatt ccctgagcag cactctgacc ctgtcaaagg 550
ccgattacga gaaacacaag gtctatgctt gcgaagtgtg acatcaggga 600
ctgtccagcc cagtgcacaa atcttttaac cgtggggagt gt 642

```

[0093] Protein Sequence Defining the Kappa Chain of the 28042 Antibody (SEQ ID NO:

10 2)

```

diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccg syspsftfgp 100
gtkvdfertv aapsvfifpp sdeqlksgta svvcllnnfy preakvqwk 150
dnalqsgnsq esvteqdskd styslssltl lskadyekhk vyacevthqg 200
15 lsspvtksfn rgec 214

```

[0094] Nucleic Acid Sequence Encoding the Kappa Chain Variable Region of the 28042 Antibody (SEQ ID NO: 18)

```

gacatccaga tgacctagtc tccatcctcc ctgtctgcat ctgtaggaga 50
20 cagagtcacc atcacttgcc gggcaagtca gagcattagc aactatttaa 100
attggtatca gcagaaacca gggaaagccc ctaagctcct gatctatgg 150
gcatccagtc tgcaaagtgg ggtcccatca agggtcagtg gcaactggatc 200
tgggacagat ttactctta ccatcagcag tctgcaacct gaagattttg 250
caacttacta ctgtcaacag agttacagtc cctcattcac tttcggccct 300
25 gggaccaaag tggatttcga a 321

```

[0095] Protein Sequence Defining the Kappa Chain Variable Region of the 28042 Antibody (SEQ ID NO: 10)

```

diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccg syspsftfgp 100
30 gtkvdfe 107

```

[0096] The amino acid sequence defining the immunoglobulin heavy chain variable region for the antibodies produced in Example 1 is shown in **FIG. 4**. Amino terminal signal peptide sequences (for proper expression/secretion) are not shown. CDR₁, CDR₂, and CDR₃ (using the Kabat system) are identified by boxes.

[0097] The amino acid sequences defining the immunoglobulin light chain variable regions for the antibodies in Example 1 are aligned in **FIG. 5**. Amino terminal signal peptide sequences (for proper expression/secretion) are not shown. CDR₁, CDR₂ and CDR₃ are identified by boxes.

- 5 [0098] Table 1 is a concordance chart showing the SEQ ID NO. of each sequence discussed in this Example.

Table 1

SEQ. ID NO.	Nucleic Acid or Protein
11	Heavy Chain of the 28042 Antibody—nucleic acid
1	Heavy Chain of the 28042 Antibody—protein
17	Heavy Chain Variable Region of the 28042 Antibody—nucleic acid
6	Heavy Chain Variable Region of the 28042 Antibody—protein
12	Kappa (light) Chain of the 28042 Antibody—nucleic acid
2	Kappa (light) Chain of the 28042 Antibody—protein
18	Kappa (light) Chain Variable Region of the 28042 Antibody—nucleic acid
10	Kappa (light) Chain Variable Region of the 28042 Antibody—protein

[0099] Human monoclonal antibody 28042 heavy chain CDR sequences (Kabat definition) are shown in Table 2.

Table 2

	CDR1	CDR2	CDR3
Kabat	DYMMS (SEQ ID NO: 3)	WIRSSGGTTLYADSVKG (SEQ ID NO: 4)	VGGGTTGYAFDI (SEQ ID NO: 5)

- 10 [00100] Human monoclonal antibody 28042 Kappa light chain CDR sequences (Kabat definition) are shown in Table 3.

Table 3

	CDR1	CDR2	CDR3
Kabat	RASQISNYLN (SEQ ID NO: 6)	GASSLQS (SEQ ID NO: 7)	QSYSPTSFT (SEQ ID NO: 8)

[00101] Nucleic Acid Sequence Encoding the Human IgG1 Heavy Chain Constant Region
(SEQ ID NO: 16)

```

5   gcctcaacaa aaggaccaag tgtgttccca ctgcccccta gcagcaagag 50
   tacatccggg ggcactgcag cactcggctg cctcgtcaag gattatatttc 100
   cagagccagt aaccgtgagc tggaacagtg gagcactcac ttctggtgtc 150
   catacttttc ctgctgtcct gcaaagctct ggctgtact cactcagctc 200
   cgtcgtgacc gtgccatctt catctctggg cactcagacc tacatctgta 250
   atgtaaacca caagcctagc aatactaagg tcgataagcg ggtggaaccc 300
10  aagagctgcg acaagactca cacttgtccc ccatgccctg cccctgaact 350
   tctgggcggg cccagcgtct ttttgttccc accaaagcct aaagatactc 400
   tgatgataag tagaacaccc gaggtgacat gtgttggtgt agacgttttc 450
   cagcaggacc cagagggtta gttcaactgg tacgttgatg gagtcgaagt 500
   acataatgct aagaccaagc ctagagagga gcagtataat agtacatacc 550
15  gtgtagtcag tgttctcaca gtgctgcacc aagactggct caacggcaaa 600
   gaatacaaat gcaaagtgtc caacaaagca ctcccagccc ctatcgagaa 650
   gactattagt aaggcaaagg ggcagcctcg tgaaccacag gtgtacactc 700
   tgccaccag tagagaggaa atgacaaaga accaagtctc attgacctgc 750
   ctgggtgaaag gcttctaccc cagcgacatc gccgttgagt gggagagtaa 800
20  cggtcagcct gagaacaatt acaagacaac cccccagtg ctggatagtg 850
   acgggtcttt ctttctgtac agtaagctga ctgtggacaa gtcccgtctg 900
   cagcagggta acgtcttcag ctgttccgtg atgcacgagg cattgcacaa 950
   ccactacacc cagaagtcac tgagcctgag cccagggaag 990

```

25 [00102] Protein Sequence Defining the Human IgG1 Heavy Chain Constant Region (SEQ ID NO: 13)

```

   astkgpsvfp lapsskstsg gtaalgclvk dyfpepvtvs wnsgaltsgv 50
   htfpavqlqs glyslssvvt vpssslgtqt yicvnvhkps ntkvdkrvep 100
   kscdkthtcp pcpapellgg psvflfppkp kdtlmisrtp evtcvvvdvs 150
30  hedpevkfnw yvdgvevhna ktkpreeqyn styrvsvlt vlhqdwlngk 200
   eykckvsnka lpapiektis kakgqprepq vytlppsree mtknqvsltc 250
   lvkgfypsdi avewesngqp ennykttppv ldsdgsffly skltvdksrw 300
   qqgnvfscsv mhealhnhyt qkslsfspgk 330

```

35 [00103] Nucleic Acid Sequence Encoding the Human Kappa Light Chain Constant Region
of the 28042 Antibody (SEQ ID NO: 15)

```

   cgaactgtgg ctgcaccatc tgtgttcac tttccaccaa gtgatgagca 50
   actgaagtct ggtactgctt cagtcgtgtg tctgctgaac aattttctacc 100
   ctcgagaagc caaagtccaa tggaaggtag acaacgcact gcagtccggc 150
40  aatagccaag aatcagttac cgaacaggat tcaaaggaca gtacatattc 200
   cctgagcagc actctgaccc tgtcaaaggc cgattacgag aaacacaagg 250

```

tctatgcttg cgaagtgaca catcaggac tgtccagccc agtgacaaaa 300
tcttttaacc gtggggagtg t 321

[00104] Protein Sequence Defining the Human Kappa Light Chain Constant Region of the 28042 Antibody (SEQ ID NO: 14)

5 rtvaapsvfi fppsdeqlks gtasvvclln nfypreakvq wkvdnalqsg 50
nsqesvteqd skdstyslss tltslkadye khkvyacevt hqglsspvtk 100
sfnrgec 107

[00105] Table 4 is a concordance chart showing the SEQ ID NO. of each sequence discussed in this Example.

10

Table 4

SEQ ID NO.	Nucleic Acid or Protein
11	28042 Heavy Human Variable Region (SEQ ID NO:17) + Human IgG1 Constant Region (SEQ ID NO:16)—nucleic acid
1	28042 Heavy Human Variable Region (SEQ ID NO:6) + Human IgG1 Constant Region (SEQ ID NO:13)—protein
12	28042 Kappa Human Variable Region (SEQ ID NO:18)+ Human Kappa Constant Region (SEQ ID NO: 15)—nucleic acid
2	28042 Kappa Human Variable Region (SEQ ID NO:10) + Human Kappa Constant Region (SEQ ID NO:14)—protein

[00106] The following sequences relate to variants of the 28042 antibody where certain residues in the framework region have been modified via germlining. The CDR sequences are underlined.

15

[00107] Protein Sequence Defining the Kappa Chain Variable Region of the 28042.1 Antibody (SEQ ID NO: 23)

20 diqmtqspss lsasvgdrvt itcrasqsis Sylnwyqqkp gkapklliyg 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccqg syspsftfgp 100
gtkvdfe 107

[00108] Protein Sequence Defining the Kappa Chain Variable Region of the 28042.2 Antibody (SEQ ID NO: 24)

25 diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyA 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccqg syspsftfgp 100
gtkvdfe 107

[00109] Protein Sequence Defining the Kappa Chain Variable Region of the 28042.3**Antibody** (SEQ ID NO: 25)

diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
 5 asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccqq syspsftfpg 100
 gtkvdIe 107

[00110] Protein Sequence Defining the Kappa Chain Variable Region of the 28042.4**Antibody** (SEQ ID NO: 26)

diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
 10 asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccqq syspsftfpg 100
 gtkvdFK 107

[00111] Protein Sequence Defining the Kappa Chain Variable Region of the 28042.5**Antibody** (SEQ ID NO: 27)

15 diqmtqspss lsasvgdrvt itcrasqsis Sylnwyqqkp gkapklliyA 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccqq syspsftfpg 100
 gtkvdfe 107

[00112] Protein Sequence Defining the Kappa Chain Variable Region of the 28042.620 **Antibody** (SEQ ID NO: 28)

diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccqq syspsftfpg 100
 gtkvdIK 107

25 **[00113] Protein Sequence Defining the Kappa Chain Variable Region of the 28042.7****Antibody** (SEQ ID NO: 29)

diqmtqspss lsasvgdrvt itcrasqsis Sylnwyqqkp gkapklliyA 50
 30 asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccqq syspsftfpg 100
 gtkvdIK 107

[00114] Protein Sequence Defining the Kappa Chain Variable Region of the 28042.8**Antibody** (SEQ ID NO: 37)

diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
 35 asslqsgvps rFsgtgsgtd ftltisslqp edfatyyccqq syspsftfpg 100
 gtkvdfe 107

[00115] Protein Sequence Defining the Kappa Chain Variable Region of the 28042.9**Antibody** (SEQ ID NO: 38)

```

diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
asslqsgvps rvsgSgsgtd ftltisslqp edfatyyccqg syspsftfgp 100
gtkvdfe 107

```

5 **[00116]** Protein Sequence Defining the Kappa Chain Variable Region of the 28042.10 Antibody (SEQ ID NO: 39)

```

diqmtqspss lsasvgdrvt itcrasqsis Sylnwyqqkp gkapklliyA 50
asslqsgvps rFsgSgsgtd ftltisslqp edfatyyccqg syspsftfgp 100
gtkvdfe 107

```

10 **[00117]** Protein Sequence Defining the Kappa Chain of the 28042.1 Antibody (SEQ ID NO: 30)

```

diqmtqspss lsasvgdrvt itcrasqsis Sylnwyqqkp gkapklliyg 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccqg syspsftfgp 100
gtkvdfertv aapsvfifpp sdeqlksgta svvcllnfy preakvqwk 150
15 dnalqsgnsq esvteqdsd styslsstlt lskadyekhk vyacevthqg 200
lsspvtksfn rgec 214

```

[00118] Protein Sequence Defining the Kappa Chain of the 28042.2 Antibody (SEQ ID NO: 31)

```

20 diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyA 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccqg syspsftfgp 100
gtkvdfertv aapsvfifpp sdeqlksgta svvcllnfy preakvqwk 150
dnalqsgnsq esvteqdsd styslsstlt lskadyekhk vyacevthqg 200
lsspvtksfn rgec 214

```

25 **[00119]** Protein Sequence Defining the Kappa Chain of the 28042.3 Antibody (SEQ ID NO: 32)

```

diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccqg syspsftfgp 100
30 gtkvdIertv aapsvfifpp sdeqlksgta svvcllnfy preakvqwk 150
dnalqsgnsq esvteqdsd styslsstlt lskadyekhk vyacevthqg 200
lsspvtksfn rgec 214

```

10

[00120] Protein Sequence Defining the Kappa Chain of the 28042.4 Antibody (SEQ ID NO: 33)

```

35 diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyyccqg syspsftfgp 100
gtkvdfKrtv aapsvfifpp sdeqlksgta svvcllnfy preakvqwk 150
dnalqsgnsq esvteqdsd styslsstlt lskadyekhk vyacevthqg 200
40 lsspvtksfn rgec 214

```

[00121] Protein Sequence Defining the Kappa Chain of the 28042.5 Antibody (SEQ ID NO:

34)

```

diqmtqspss lsasvgdrvt itcrasqsis Sylnwyqqkp gkapklliyA 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyycgg syspsftfpg 100
5 gtkvdfertv aapsvfifpp sdeqlksgta svvcllnnfy preakvqwk 150
dnalqsgnsq esvteqdsd styslsstlt lskadyekhk vyacevthqg 200
lsspvtksf n rgec 214

```

[00122] Protein Sequence Defining the Kappa Chain of the 28042.6 Antibody (SEQ ID NO:

10 35)

```

diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyycgg syspsftfpg 100
gtkvdIKrtv aapsvfifpp sdeqlksgta svvcllnnfy preakvqwk 150
dnalqsgnsq esvteqdsd styslsstlt lskadyekhk vyacevthqg 200
15 lsspvtksf n rgec 214

```

[00123] Protein Sequence Defining the Kappa Chain of the 28042.7 Antibody (SEQ ID NO:

36)

```

diqmtqspss lsasvgdrvt itcrasqsis Sylnwyqqkp gkapklliyA 50
asslqsgvps rvsgtgsgtd ftltisslqp edfatyycgg syspsftfpg 100
20 gtkvdIKrtv aapsvfifpp sdeqlksgta svvcllnnfy preakvqwk 150
dnalqsgnsq esvteqdsd styslsstlt lskadyekhk vyacevthqg 200
lsspvtksf n rgec 214

```

[00124] Protein Sequence Defining the Kappa Chain of the 28042.8 Antibody (SEQ ID NO:

25 40)

```

diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
asslqsgvps rFsgtgsgtd ftltisslqp edfatyycgg syspsftfpg 100
gtkvdertv aapsvfifpp sdeqlksgta svvcllnnfy preakvqwk 150
dnalqsgnsq esvteqdsd styslsstlt lskadyekhk vyacevthqg 200
30 lsspvtksf n rgec 214

```

[00125] Protein Sequence Defining the Kappa Chain of the 28042.9 Antibody (SEQ ID NO:

41)

```

diqmtqspss lsasvgdrvt itcrasqsis nylnwyqqkp gkapklliyg 50
35 asslqsgvps rvsgSgsgtd ftltisslqp edfatyycgg syspsftfpg 100
gtkvdertv aapsvfifpp sdeqlksgta svvcllnnfy preakvqwk 150
dnalqsgnsq esvteqdsd styslsstlt lskadyekhk vyacevthqg 200
lsspvtksf n rgec 214

```

[00126] Protein Sequence Defining the Kappa Chain of the 28042.10 Antibody (SEQ ID NO: 42)

5 diqmtqspss lsasvgdrvt itcrasgsis Sylnwyqqkp gkapklliyA 50
asslqsgvps rFsgSgsgtd ftltisslqp edfatyycgg syspsftfgp 100
 gtkvdfertv aapsvfifpp sdeqlksgta svvcllnfy preakvqwk 150
 dnalqsgnsq esvteqdskd styslsstlt lskadyekhk vyacevthqg 200
 lsspvtksfn rgec 214

[00127] Table 5 provides the heavy chain and light chain full length sequences for the 28042 antibody and antibody variants 28042.1-28042.10.

Table 5

Antibody Name	Heavy Chain Protein Sequence	Light Chain Protein Sequence
28042	SEQ ID NO:1	SEQ ID NO:2
28042.1	SEQ ID NO:1	SEQ ID NO:30
28042.2	SEQ ID NO:1	SEQ ID NO:31
28042.3	SEQ ID NO:1	SEQ ID NO:32
28042.4	SEQ ID NO:1	SEQ ID NO:33
28042.5	SEQ ID NO:1	SEQ ID NO:34
28042.6	SEQ ID NO:1	SEQ ID NO:35
28042.7	SEQ ID NO:1	SEQ ID NO:36
28042.8	SEQ ID NO:1	SEQ ID NO:40
28042.9	SEQ ID NO:1	SEQ ID NO:41
28042.10	SEQ ID NO:1	SEQ ID NO:42

[00128] Table 6 provides combinations of heavy chain variable region protein sequences, heavy chain constant region sequences, light chain variable region sequences and light chain constant region sequences for the 28042 antibody and antibody variants 28042.1-28042.10.

Table 6

Antibody Name	Heavy Chain Variable Protein Sequence	Heavy Chain Constant Region Sequence	Light Chain Variable Region Sequence	Light Chain Constant Region Sequence
28042	SEQ ID NO:6	SEQ ID NO:13	SEQ ID NO:10	SEQ ID NO:14
28042.1	SEQ ID NO:6	SEQ ID NO:13	SEQ ID NO:23	SEQ ID NO:14

Antibody Name	Heavy Chain Variable Protein Sequence	Heavy Chain Constant Region Sequence	Light Chain Variable Region Sequence	Light Chain Constant Region Sequence
28042.2	SEQ ID NO:6	SEQ ID NO:13	SEQ ID NO:24	SEQ ID NO:14
28042.3	SEQ ID NO:6	SEQ ID NO:13	SEQ ID NO:25	SEQ ID NO:14
28042.4	SEQ ID NO:6	SEQ ID NO:13	SEQ ID NO:26	SEQ ID NO:14
28042.5	SEQ ID NO:6	SEQ ID NO:13	SEQ ID NO:27	SEQ ID NO:14
28042.6	SEQ ID NO:6	SEQ ID NO:13	SEQ ID NO:28	SEQ ID NO:14
28042.7	SEQ ID NO:6	SEQ ID NO:13	SEQ ID NO:29	SEQ ID NO:14
28042.8	SEQ ID NO:6	SEQ ID NO:13	SEQ ID NO:37	SEQ ID NO:14
28042.9	SEQ ID NO:6	SEQ ID NO:13	SEQ ID NO:38	SEQ ID NO:14
28042.10	SEQ ID NO:6	SEQ ID NO:13	SEQ ID NO:39	SEQ ID NO:14

[00129] Table 7 discloses the CDR sequences for antibody 28042 and variants 28042.1-28042.10.

Table 7

Antibody	CDR _{H1}	CDR _{H2}	CDR _{H3}	CDR _{L1}	CDR _{L2}	CDR _{L3}
28042	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9
28042.1	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:21	SEQ ID NO:8	SEQ ID NO:9
28042.2	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:7	SEQ ID NO:22	SEQ ID NO:9
28042.3	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9
28042.4	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9
28042.5	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:21	SEQ ID NO:22	SEQ ID NO:9
28042.6	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9
28042.7	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:21	SEQ ID NO:22	SEQ ID NO:9
28042.8	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9

Antibody	CDR _{H1}	CDR _{H2}	CDR _{H3}	CDR _{L1}	CDR _{L2}	CDR _{L3}
28042.9	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9
28042.10	SEQ ID NO:3	SEQ ID NO:4	SEQ ID NO:5	SEQ ID NO:21	SEQ ID NO:22	SEQ ID NO:9

Example 2: Binding Affinities

[00130] The binding affinity and kinetics of binding of the 28042 antibody to recombinant human Notch3 extracellular domain (containing EGF like domains 1-11) Fc fusion protein (rhNotch3-Fc (R&D Systems, Inc., Minneapolis, MN)) can be measured by surface plasmon resonance using a Biacore[®] T100 instrument (GE Healthcare, Piscataway, NJ).

[00131] Goat anti-human IgG is immobilized on carboxymethylated dextran CM4 sensor chips (GE Healthcare) by amine coupling, according to a standard protocol. Analyses are performed at 25°C and 37°C using PBS containing 0.05% surfactant P20 as running buffer. The antibody is captured in individual flow cells at a flow rate of 10 µl/minute. Injection time is varied for each antibody to yield an R_{max} between 30 and 60 resonance units (RU). 250 µg/mL human IgG Fc is injected to block non-specific binding of Fc (from the Notch3 fusion protein) to the capture antibody. Buffer or rhNotch3-Fc diluted in running buffer is injected sequentially over a reference surface (no antibody captured) and the active surface (antibody to be tested) for 240 seconds at 60 µL/minute. The dissociation phase is monitored for up to 1500 seconds. The surface is then regenerated with two 60-second injections of 10 mM Glycine-HCl, pH 2.25, at a flow rate of 30 µL/minute. The rhNotch3-Fc concentration range tested is 100 nM to 3.125 nM (2 fold dilution).

[00132] Kinetic parameters can be determined using the kinetic function of the BIAevaluation software (GE Healthcare) with double reference subtraction. Kinetic parameters for the antibody, k_a (association rate constant), k_d (dissociation rate constant) and K_D (equilibrium dissociation constant) are determined.

[00133] Kinetic values of the monoclonal antibody 28042 on rhNotch3-Fc at 25°C and 37°C are summarized in Table 8.

Table 8**Antibody Binding to rhNotch3-Fc**

Temperature	k_a (1/Ms)	k_d (1/s)	K_D (M)
25°C	1.77E+05	2.99E-04	2.55E-09
37°C	9.47E+04	3.96E-04	4.18E-09

[00134] The data in Table 8 demonstrate that the 28042 antibody binds rhNotch3-Fc with a K_D of about 1-10 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 900 pM, 850 pM, 800 pM, 750 pM, 700 pM, 650 pM, 600 pM, 500 pM, 400 pM, 300 pM, or 200 pM or less.

[00135] Binding to cell surface human Notch3 by the antibody 28042 can be measured at 4°C, using Fluorescence Activated Cell Sorting (FACS). CHO N3 (Flp-In-CHO cells

(Invitrogen) stably transfected with human Notch3), HCC2429 cells, and RL-952 cells expressing human Notch3 are washed once with PBS containing calcium chloride and magnesium chloride (Invitrogen) and harvested using cell dissociation buffer (Invitrogen). Cells are washed a second time with PBS and resuspended in FACS buffer (PBS with 0.5 % BSA (Sigma-Aldrich)) for a final cell concentration of 250,000 cells per well into a 96-well v-bottom plate. Purified antibodies are diluted in FACS buffer over a concentration range of 100 nM to 0 nM. Cells are then incubated at 4°C with 100 μ L of antibody for one hour, washed with FACS buffer twice, and resuspended in 100 μ L of goat-anti mouse PE-conjugated antibody (Jackson Immuno Research). Cells are incubated at 4°C for 30 minutes in the dark, washed once with FACS buffer, and then analyzed using a Beckman Coulter Cytomics FC 500 instrument. The geometric mean of the florescent intensity then is calculated for each antibody concentration. These values then are entered into Prism software (GraphPad, La Jolla, CA) and used to generate a binding curve by plotting geometric mean versus antibody concentration. From the binding curve, the following equation is used to calculate the K_D and K_D range of 28042 antibody binding to human Notch3 on the cell surface of the three cell lines.

Equation: One site binding (hyperbola)

$$Y = B_{\max} * X / (K_D + X)$$

* describes the binding of a ligand to a receptor that follows the law of mass action. $B_{\max}$ is

the maximal binding, and K_D is the concentration of ligand required to reach half-maximal binding.

[00136] The results for the 28042 antibody are summarized in Table 9.

Table 9

5

Binding to hNotch3 on Cell Surface

K_D (nM)	K_D Range (nM)
2.723	1.794 to 3.652

[00137] The data in Table 9 demonstrate that the 28042 antibody binds rhNotch3-Fc with a K_D of about 1-10 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 900 pM, 850 pM, 800 pM, 750 pM, 700 pM, 650 pM, 600 pM, 500 pM, 400 pM, 300 pM, or 200 pM or less.

10 [00138] K_D values for the binding of the 28042 and 28042.1-28042.7 antibodies to cynoNotch3 was tested according to a similar protocol as described above for 28042 antibody binding to hNotch3, and the results are shown in Table 10.

Table 10

Binding to cynoNotch3 monomer at 25°C

Antibody	K_D (M)
28042.1	5.35E-09
28042.2	2.14E-07
28042.3	2.65E-07
28042.4	3.36E-07
28042.5	2.11E-07
28042.6	1.92E-07
28042.7	2.51E-07
28042	8.06E-07

15 **Example 3: Binding Specificity**

[00139] In this example, the binding specificity of the 28042 antibody for human Notch1, human Notch2, human Notch3, or murine Notch3 proteins is described.

[00140] The specificity of the 28042 antibody binding for Notch-Fc fusion proteins can be determined using surface plasmon resonance using a Biacore® T100 instrument (GE Healthcare, Piscataway, NJ). Rabbit anti-mouse IgGs (GE Healthcare) are immobilized on carboxymethylated dextran CM4 sensor chips (GE Healthcare) by amine coupling, according to a standard protocol. Analyses are performed at 25°C and 37°C using PBS containing 0.05% surfactant P20 as running buffer. The antibody is captured in individual flow cells at a flow rate of 10 µL/minute. Injection time is varied for each antibody to yield an Rmax between 30 and 60 RU. 250 µg/mL human IgG Fc is injected to block non-specific binding of Fc (from the Notch3 fusion protein) to the capture antibody. Buffer or rhNotch1-Fc (R&D Systems, Minneapolis, MN; Cat. No. 3647-TK-050), rhNotch2-Fc (R&D Cat. No. 3735-NT-050), and rhNotch3-Fc (R&D Cat. No. 1559-NT-050), diluted in running buffer is injected sequentially over a reference surface (no antibody captured) and the active surface (antibody to be tested) for 240 seconds at 60 µL/minute. The dissociation phase is monitored for up to 1500 seconds. The surface is then regenerated with two 60-second injections of 10 mM Glycine-HCl, pH 2.25, at a flow rate of 30 µL/minute. The rhNotch3-Fc, rhNotch2-Fc, and rhNotch1-Fc concentration range tested are 100 nM to 3.125 nM (2 fold dilution).

[00141] As shown in FIG. 6, the specificity of the 28042 antibody binding to the extracellular domains of Notch1-Fc, Notch2-Fc, and Notch3-Fc fusion proteins was measured at three different dilutions by surface plasmon resonance. As shown in FIG. 6, the binding affinity of the 28042 antibody for Notch3 is high while there is no appreciable binding of the 28042 antibody to Notch1 or Notch2.

[00142] To determine the specificity of binding to cell surface Notch proteins, stable cells lines expressing Notch receptors are produced by transfecting FlpIn™ CHO or FlpIn™ 293 cells (Life Technologies, Grand Island, NY) with full length human Notch1, Notch2, Notch3, or full length murine Notch3 cDNAs cloned into the pcDNA5FRT vector using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. Twenty-four hours after transfection, CHO cells are split into F12 media containing 10% FBS, 2 mM L-Glutamine and 600-700 µg/ml hygromycin B (Sigma-Aldrich, St. Louis, MO) to select for transfected cells. 293 cells are split into DMEM media containing 10% FBS, 2mM L-glutamine and 200 µg/ml hygromycin B. Expression of Notch receptors can be confirmed by FACS analysis using anti-human Notch1 PE (BioLegend, San Diego, CA), anti-Notch2 PE (eBioscience, San Diego, CA), or anti-human Notch3 PE (BioLegend, San Diego, CA).

[00143] To determine the specificity of binding to cell surface Notch proteins, the 28042 antibody is tested for binding to human Notch1, human Notch2, human Notch3 and murine Notch3 expressed on the surface of CHO cells by FACS analysis. Full length Notch receptor cDNAs cloned into pcDNA5FRT were transfected into FlpIn™ CHO cells and selected with 5 600 µg/ml hygromycin (Sigma), according to the manufacturer's protocol. Cell surface expression of Notch receptors is confirmed by FACS analysis using anti-Notch1 PE, anti-Notch2 PE or anti-Notch3 PE control antibodies (Biolegend). FlpIn™ CHO cells expressing Notch receptors are incubated with 5 µg/ml 28042 antibody or human IgG control antibody (Jackson ImmunoResearch) for 1 hour on ice, followed by washing with PBS/0.5% BSA, and 10 incubation with anti-human PE secondary antibody (Biolegend) for 30 minutes on ice. FACS is performed on a BD FACSCanto II cell analyzer (BD Biosciences) and analyzed using FlowJo software.

[00144] As shown in FIG. 7, FACS binding data demonstrates that the 28042 antibody specifically binds to human Notch3 and murine Notch3, with no cross reactivity with human 15 Notch1 or human Notch2.

[00145] To determine the specificity of binding to cell surface Notch proteins, the 28042 antibody is tested for binding to human Notch1, human Notch2, human Notch3 and murine Notch3 expressed on the surface of CHO cells using electrochemiluminescence (Meso Scale Discovery). A CHO line lacking any human Notch protein is used as a negative control. Cells 20 are grown under standard conditions (37°C, F12 + 10% FBS). For binding studies, cells are washed in PBS containing calcium and magnesium, and removed from the plate by treatment with Cell Dissociation Buffer (Life Technologies) for ten minutes at 37°C.

[00146] Cells are seeded at a density of 30,000 cells per well, in hybridoma media, in a standard 96-well binding plates (Meso Scale Discovery, Cat. No. L15XA-6). Cells are 25 incubated for one hour at 37°C. Antibodies or control IgG are added at 5 µg/mL, in 50 µL hybridoma media, and incubated for one hour at 37°C. The plates are washed twice with PBS containing 3% BSA. Binding of the antibodies to cell surface is detected using 2 µg/mL of MSD anti-mouse IgG secondary antibody (Meso Scale Discovery, Cat. No. R32AC-1) for one hour at 4°C. Plates are washed twice with PBS containing 3% BSA, and 150 µL of read buffer 30 (Meso Scale Discovery Cat. No. R92TC-1) is added. The plates are analyzed on a Sector Imager 2400 instrument (Meso Scale Discovery).

Examples 4: Inhibition of Notch3-Ligand Binding

[00147] The 28042 antibody can be tested for its ability to inhibit the binding of rhNotch3 binding to human Jag1, Jag2, DLL1 and DLL4. Binding measurements are made by bio-layer interferometry (BLI), using a FortéBio Octet® QK instrument (FortéBio, Menlo Park, CA).

- 5 The ligands tested are rhJag1-Fc (R&D Cat. No. 1277-JG-050), rhJag2-Fc (R&D Cat. No. 1726-JG-050), rhDLL1-Fc (R&D Cat. No. 5026-DL-050), and His tagged rhDLL4 (R&D Cat. No. 1506-D4-050).

- [00148] To determine the degree of inhibition of Notch3-ligand binding by the 28042 antibody, the Octet sensors are loaded with recombinant human Notch3, and the antibody is allowed to bind. Then sensors are immersed in 500 µg/mL human IgG to block non-specific binding. Ligands are prepared at a concentration of 400 nM in PBS containing 3% BSA, and are allowed to bind. The on-rate and off-rate for ligand binding are detected using the Octet QK instrument and software.
- 10

Example 5: Inhibition of Ligand-Induced Notch3 ICD Cleavage

- 15 [00149] Activation of Notch receptors by ligands results in cleavage of the Notch intracellular domain (NICD), which can be detected by Western blot. In this example, the 28042 antibody is tested for its ability to inhibit ligand-induced cleavage of the Notch3 ICD.

- [00150] To create soluble Notch ligands, PCR is used to amplify sequences corresponding to the extracellular domains of human Jag1 or human Jag2 cDNA and fuse them in-frame to the coding sequence of human or murine IgG Fc. This construct then is subcloned into the pEE14.4 expression vector (Lonza), transfected into CHOK1SV cells, and selected to produce stable cell lines that secrete hJag1-hFc, hJag1-mFc, hJag2-hFc, or hJag2-mFc fusion protein. Fusion proteins are purified from cell supernatants.
- 20

- [00151] In one experiment, mNotch3 expressing cells are incubated with the Notch3 ligand Jag1, and ligand-induced cleavage of the mNotch3 ICD is measured by Western blot. The 28042 antibody is further added to test for its ability to inhibit ligand-induced cleavage of the mNotch3 ICD. 96-well Immunosorp ELISA plates (Nalgene Nunc, Rochester, NY) are coated with 5 µg/ml anti-mouse Fc (Jackson ImmunoResearch, West Grove, PA) overnight at 4°C. After washing wells with PBS/0.5% BSA, 5 µg/ml of soluble hJag1-mFc fusion protein is added and allowed to bind at room temperature for two hours. Unbound protein is removed by
- 25
- 30

washing with PBS/0.5% BSA. 293 FlpIn™ cells engineered to express mNotch3 (produced as described in Example 3) are plated on captured ligand or mFc in the presence of 10 µg/mL human IgG control, the 28042 antibody, the Notch 3 antibody ABX, or an antibody specific for human Notch 3 (04F11). Cells are lysed 24 hours later in RIPA buffer (Boston BioProducts, Ashland, MA) containing protease inhibitors. Lysates are run on SDS PAGE, and transferred to nitrocellulose. Induction of NICD cleavage can be detected by probing with an antibody against the Notch3 C-terminus (Cell Signaling, Danvers, MA) that detects both full length protein and the cleaved ICD.

[00152] As shown in FIG. 8, plating mNotch3 293 FlpIn™ cells on Jag1-mFc ligand induces ICD cleavage and activation of the receptor. Addition of the 28042 antibody diminishes ligand-induced cleavage and activation of mNotch3, while the addition of a human IgG control or a human Notch3 control antibody has no effect on mNotch3 ICD cleavage.

[00153] In another experiment, Notch3 expressing cells are incubated with the Notch3 ligand DLL4, and ligand-induced cleavage of the Notch3 ICD is measured by Western blot.

The 28042 antibody is further added to test for its ability to inhibit ligand-induced cleavage of the Notch3 ICD. 96-well Immunosorp ELISA plates are coated with 5 µg/mL His tag antibody (R&D Systems, Minneapolis, MN) overnight at 4°C, after which 5 µg/mL DLL4-His fusion protein (R&D Systems, Minneapolis, MN), is added and allowed to bind for two hours at room temperature. Unbound protein is removed by washing with PBS/0.5% BSA. NCI-H838 cells are plated on captured ligand in the presence of 10 µg/mL human IgG control, the 28042 antibody, the Notch 3 antibody ABX, or an antibody specific for human Notch 3 (04F11). Cells are lysed 24 hours later in RIPA buffer (Boston BioProducts, Ashland, MA) containing protease inhibitors. Lysates are run on SDS PAGE, and transferred to nitrocellulose. Induction of NICD cleavage can be detected by probing with an antibody against the Notch3 C-terminus (Cell Signaling, Danvers, MA) that detects both full length protein and the cleaved ICD.

[00154] NCI-H838 cells exhibit low levels of constitutive human Notch3 activation as evidenced by the presence of cleaved N3 ICD even in absence of exogenous ligand, as shown in the Western blot in FIG. 9. As shown in FIG. 9, the 28042 antibody blocks further cleavage and activation of the Notch3 receptor in response to DLL4 stimulation and reduces the level of cleaved Notch3 ICD to below baseline levels, while a human IgG control antibody had no effect on Notch3 cleavage and activation.

[00155] In another experiment, murine or human Notch3 expressing cells are incubated with the Notch3 ligands Jag1, Jag2, and DLL4, and ligand-induced cleavage of the Notch3 ICD is measured by Western blot. The 28042 antibody is further added to test for its ability to inhibit ligand-induced cleavage of the Notch3 ICD. 96-well Maxisorp plates (Nunc) are coated overnight with 5µg/ml anti-His tag (R&D Systems) or anti-mFc (Jackson ImmunoResearch) antibodies. After washing, 5µg/ml recombinant DLL4 (R&D Systems, Minneapolis, MN), hJag1-mFc, or hJag2-mFc in PBS/0.5% BSA are added and allowed to bind for two hours at room temperature. No ligand control wells are coated with anti-mFc antibody overnight and incubated with 5µg/ml mFc (Jackson ImmunoResearch). FlpInTM CHO cells stably expressing human Notch3 or murine Notch3 are pre-incubated with 10 µg/ml of the 28042 antibody or hIgG control antibody for 30 minutes before plating 30,000 cells per well onto ligand-coated plates and incubating at 37°C overnight. Cells are lysed 24 hours later in RIPA buffer (Boston BioProducts, Ashland, MA) containing protease inhibitors. Lysates are run on SDS PAGE, and transferred to nitrocellulose. Induction of NICD cleavage can be detected by probing with an antibody against the Notch3 C-terminus (Cell Signaling, Danvers, MA) that detects both full length protein and the cleaved ICD. An antibody against GAPDH (Cell Signaling) is used as a loading control. Bands are detected using an Odyssey CLx imaging system and Image Studio software (LI-COR).

[00156] As shown in FIG. 10, in mouse (FIG. 10A) and human (FIG. 10B) Notch3-expressing cells, the 28042 antibody blocks Jag1, Jag2 or DLL4 ligand-induced cleavage and activation of Notch3.

[00157] Collectively, these results demonstrate the ability of the 28042 antibody to inhibit ligand-induced activation of Notch3.

Example 6: Inhibition of Notch3-Dependent Transcription

[00158] In this example, the 28042 antibody is tested for its ability to inhibit the transcription of Notch3 target genes. Reporter cells are generated that expressed luciferase in response to Notch3 activation, and the resulting luminescence is measured in the presence or absence of the 28042 antibody.

[00159] Reporter cell lines dependent upon Notch3 are produced via the lentiviral introduction of a RBP-Jκ-dependent luciferase reporter gene (SABiosciences, Frederick, MD) into 293-FlpIn Notch3 cells, RL95-2 endometrial cancer cells, HCC1143 breast cancer cells,

and MDA-MB-468 breast cancer cells. To activate Notch3-dependent signaling and transcription, cells are plated on ligand-coated wells prepared as described in Example 5. Cells are pre-incubated with a 3-fold dilution series of Notch3 antibodies at concentrations ranging from 0-300 µg/mL, for one hour at 37°C, before seeding 100 µl of the suspension into 96-well plates coated with ligand or hFc. Cells are incubated in ligand-coated or murine-Fc-coated wells for four or twenty-four hours at 37°C, in 5% CO₂. Then, 100 µL of Promega Bright Glo™ (Promega, Madison, WI) is added to each well. The reaction is allowed to proceed for five minutes in the dark, and then the entire 200 µL volume is transferred into plates for analysis in a luminometer. Polyclonal antibodies directed against Notch1 (AF1057, R&D Systems), Notch2 (AF1190, R&D Systems) or Notch3 (AF1559, R&D Systems) are used as controls to confirm that ligand-stimulated reporter activity in each cell line is specifically dependent upon the introduced Notch receptor.

[00160] Data for a Notch3 Luciferase reporter assay for antibody 28042 is shown in FIG. 11. In this assay, cells of a MDA-MB-468 reporter cell line expressing endogenous human Notch3 and a RBP-Jκ luciferase reporter construct are plated on hJag2-mFc in the presence of Notch3 inhibitory antibodies. As shown therein, the 28042 antibody strongly inhibits the luminescent signal that results from Notch3 dependent transcription. The results demonstrate that the 28042 antibody inhibits Notch3-dependent transcription stimulated by the Jag2 ligand.

Example 7: Inhibition of Tumor Growth

[00161] In this example, the 28042 antibody is tested for its ability to inhibit tumor growth *in vivo* in a genetically engineered Notch3-driven tumor model that overexpresses and is dependent on mNotch3 for tumor maintenance. Approximately eleven week old NCR nude mice (Taconic, Germantown, NY) are inoculated subcutaneously into the right flank with 2×10^5 cells in 1:1 HBSS + Matrigel (Invitrogen, Carlsbad, CA)/Matrigel (BD Biosciences, San Jose, CA). Tumor measurements are taken twice weekly, using vernier calipers. Tumor volume is calculated using the formula: $V = 0.5 \times \text{width} \times \text{width} \times \text{length}$. When tumors approach a volume of 150-200 mm³, mice are randomized into three groups of ten animals each. The next day, mice are treated with 20 mg/kg hIgG (control) or 20 mg/kg of the 28042 antibody or the ABX antibody by intraperitoneal injection. Mice are dosed twice weekly for the duration of the study. Forty-eight hours after final dosing, tumor volumes are measured again to assess tumor growth inhibition. All statistical analysis is done using GraphPad PRISM® Version 4.00. Final

tumor volumes are analyzed using a one-way analysis of variance and Tukey multiple comparison test.

[00162] As shown in FIG. 12A, the treatment group (*i.e.*, animals receiving the 28042 antibody) shows significant tumor growth inhibition, as compared to hIgG treated controls .

5 All treatments are well-tolerated with no significant body weight loss.

[00163] As shown in FIG. 12B, lysates from harvested tumor cells treated with the 28042 antibody showed a significant decrease in human Notch3 ICD cleavage over those treated with the control antibody, showing that the 28042 antibody reduces Notch3 activation in tumor cells.

INCORPORATION BY REFERENCE

10 [00164] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.

EQUIVALENTS

[00165] The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be
15 considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and the range of equivalency of the claims are intended to be embraced therein.

What is claimed is:

- 1 1. An isolated antibody that binds human Notch3 comprising
 - 2 (i) an immunoglobulin heavy chain variable region comprising a CDR_{H1}
3 comprising the amino acid sequence of SEQ ID NO: 3, a CDR_{H2} comprising the amino
4 acid sequence of SEQ ID NO: 4, and a CDR_{H3} comprising the amino acid sequence of
5 SEQ ID NO: 5; and
 - 6 (ii) an immunoglobulin light chain variable region comprising a CDR_{L1} comprising
7 the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 21, a CDR_{L2} comprising the
8 amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 22, and a CDR_{L3} comprising the
9 amino acid sequence of SEQ ID NO: 9.
- 1 2. The isolated antibody of claim 1, wherein the immunoglobulin light chain variable
2 region comprises a CDR_{L1} comprising the amino acid sequence of SEQ ID NO: 7, a CDR_{L2}
3 comprising the amino acid sequence of SEQ ID NO: 8, and a CDR_{L3} comprising the amino acid
4 sequence of SEQ ID NO: 9.
- 1 3. The isolated antibody of claim 1, wherein the immunoglobulin light chain variable
2 region comprises a CDR_{L1} comprising the amino acid sequence of SEQ ID NO: 21, a CDR_{L2}
3 comprising the amino acid sequence of SEQ ID NO: 8, and a CDR_{L3} comprising the amino acid
4 sequence of SEQ ID NO: 9.
- 1 4. The isolated antibody of claim 1, wherein the immunoglobulin light chain variable
2 region comprises a CDR_{L1} comprising the amino acid sequence of SEQ ID NO: 7, a CDR_{L2}
3 comprising the amino acid sequence of SEQ ID NO: 22, and a CDR_{L3} comprising the amino
4 acid sequence of SEQ ID NO: 9.
- 1 5. The isolated antibody of claim 1, wherein the immunoglobulin light chain variable
2 region comprises a CDR_{L1} comprising the amino acid sequence of SEQ ID NO: 21, a CDR_{L2}
3 comprising the amino acid sequence of SEQ ID NO: 22, and a CDR_{L3} comprising the amino
4 acid sequence of SEQ ID NO: 9.
- 1 6. An isolated nucleic acid comprising a nucleotide sequence encoding an
2 immunoglobulin heavy chain variable region of claim 1.

- 1 7. An isolated nucleic acid comprising a nucleotide sequence encoding an
2 immunoglobulin light chain variable region of any one of claims 1-5.
- 1 8. An expression vector comprising the nucleic acid of claim 5.
- 1 9. An expression vector comprising the nucleic acid of claim 6.
- 1 10. The expression vector of claim 8, further comprising the nucleic acid of claim 5.
- 1 11. A host cell comprising the expression vector of claim 7.
- 1 12. A host cell comprising the expression vector of claim 8.
- 1 13. A host cell comprising the expression vector of claim 9.
- 1 14. The host cell of claim 11, further comprising the expression vector of claim 7.
- 1 15. A method of producing a polypeptide comprising an immunoglobulin heavy chain
2 variable region or an immunoglobulin light chain variable region, the method comprising:
3 (a) growing the host cell of claim 10 or 11 under conditions so that the host cell
4 expresses the polypeptide comprising the immunoglobulin heavy chain variable region
5 or the immunoglobulin light chain variable region; and
6 (b) purifying the polypeptide comprising the immunoglobulin heavy chain variable
7 region or the immunoglobulin light chain variable region.
- 1 16. A method of producing an antibody that binds human Notch3 or an antigen binding
2 fragment of the antibody, the method comprising:
3 (a) growing the host cell of claim 12 or 13 under conditions so that the host cell
4 expresses a polypeptide comprising the immunoglobulin heavy chain variable region
5 and the immunoglobulin light chain variable region, thereby producing the antibody or
6 the antigen-binding fragment of the antibody; and
7 (b) purifying the antibody or the antigen-binding fragment of the antibody.
- 1 17. An isolated antibody that binds human Notch3, comprising an immunoglobulin heavy
2 chain variable region comprising the amino acid sequence of SEQ ID NO:6, and an

3 immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID
4 NO:10, 23, 24, 25, 26, 27, 28, 29, 37, 38, or 39.

1 18. The isolated antibody of claim 16, wherein the immunoglobulin light chain variable
2 region comprises the amino acid sequence of SEQ ID NO:10.

1 19. The isolated antibody of claim 16, wherein the immunoglobulin light chain variable
2 region comprises the amino acid sequence of SEQ ID NO:23.

1 20. The isolated antibody of claim 16, wherein the immunoglobulin light chain variable
2 region comprises the amino acid sequence of SEQ ID NO:24.

1 21. The isolated antibody of claim 16, wherein the immunoglobulin light chain variable
2 region comprises the amino acid sequence of SEQ ID NO:25.

1 22. The isolated antibody of claim 16, wherein the immunoglobulin light chain variable
2 region comprises the amino acid sequence of SEQ ID NO:26.

1 23. The isolated antibody of claim 16, wherein the immunoglobulin light chain variable
2 region comprises the amino acid sequence of SEQ ID NO:27.

1 24. The isolated antibody of claim 16, wherein the immunoglobulin light chain variable
2 region comprises the amino acid sequence of SEQ ID NO:28.

1 25. The isolated antibody of claim 16, wherein the immunoglobulin light chain variable
2 region comprises the amino acid sequence of SEQ ID NO:29.

1 26. The isolated antibody of claim 16, wherein the immunoglobulin light chain variable
2 region comprises the amino acid sequence of SEQ ID NO:37.

1 27. The isolated antibody of claim 16, wherein the immunoglobulin light chain variable
2 region comprises the amino acid sequence of SEQ ID NO:38.

1 28. The isolated antibody of claim 16, wherein the immunoglobulin light chain variable
2 region comprises the amino acid sequence of SEQ ID NO:39.

- 1 29. An isolated nucleic acid comprising a nucleotide sequence encoding the
2 immunoglobulin heavy chain variable region of claim 16.
- 1 30. An isolated nucleic acid comprising a nucleotide sequence encoding the
2 immunoglobulin light chain variable region of any one of claims 16-27.
- 1 31. An expression vector comprising the nucleic acid of claim 28.
- 1 32. An expression vector comprising the nucleic acid of claim 29.
- 1 33. The expression vector of claim 31, further comprising the nucleic acid of claim 28.
- 1 34. A host cell comprising the expression vector of claim 30.
- 1 35. A host cell comprising the expression vector of claim 31.
- 1 36. A host cell comprising the expression vector of claim 32.
- 1 37. The host cell of claim 34, further comprising the expression vector of claim 30.
- 1 38. A method of producing a polypeptide comprising an immunoglobulin heavy chain
2 variable region or an immunoglobulin light chain variable region, the method comprising:
3 (a) growing the host cell of claim 33 or 34 under conditions so that the host cell
4 expresses the polypeptide comprising the immunoglobulin heavy chain variable region
5 or the immunoglobulin light chain variable region; and
6 (b) purifying the polypeptide comprising the immunoglobulin heavy chain variable
7 region or the immunoglobulin light chain variable region.
- 1 39. A method of producing an antibody that binds human Notch3 or an antigen binding
2 fragment of the antibody, the method comprising:
3 (a) growing the host cell of claim 35 or 36 under conditions so that the host cell
4 expresses a polypeptide comprising the immunoglobulin heavy chain variable region
5 and the immunoglobulin light chain variable region, thereby producing the antibody or
6 the antigen-binding fragment of the antibody; and
7 (b) purifying the antibody or the antigen-binding fragment of the antibody.

1 40. An isolated antibody that binds human Notch3 comprising an immunoglobulin heavy
2 chain comprising the amino acid sequence of SEQ ID NO: 1, and an immunoglobulin light
3 chain comprising the amino acid sequence selected from SEQ ID NO: 2, 30, 31, 32, 33, 34, 35,
4 36, 40, 41, or 42.

1 41. The isolated antibody of claim 39, wherein the immunoglobulin light chain comprises
2 the amino acid sequence of SEQ ID NO:2.

1 42. The isolated antibody of claim 39, wherein the immunoglobulin light chain comprises
2 the amino acid sequence of SEQ ID NO:30.

1 43. The isolated antibody of claim 39, wherein the immunoglobulin light chain comprises
2 the amino acid sequence of SEQ ID NO:31.

1 44. The isolated antibody of claim 39, wherein the immunoglobulin light chain comprises
2 the amino acid sequence of SEQ ID NO:32.

1 45. The isolated antibody of claim 39, wherein the immunoglobulin light chain comprises
2 the amino acid sequence of SEQ ID NO:33.

1 46. The isolated antibody of claim 39, wherein the immunoglobulin light chain comprises
2 the amino acid sequence of SEQ ID NO:34.

1 47. The isolated antibody of claim 39, wherein the immunoglobulin light chain comprises
2 the amino acid sequence of SEQ ID NO:35.

1 48. The isolated antibody of claim 39, wherein the immunoglobulin light chain comprises
2 the amino acid sequence of SEQ ID NO:36.

1 49. The isolated antibody of claim 39, wherein the immunoglobulin light chain comprises
2 the amino acid sequence of SEQ ID NO:40.

1 50. The isolated antibody of claim 39, wherein the immunoglobulin light chain comprises
2 the amino acid sequence of SEQ ID NO:41.

- 1 51. The isolated antibody of claim 39, wherein the immunoglobulin light chain comprises
2 the amino acid sequence of SEQ ID NO:42.
- 1 52. An isolated nucleic acid comprising a nucleotide sequence encoding an
2 immunoglobulin heavy chain of claim 39.
- 1 53. An isolated nucleic acid comprising a nucleotide sequence encoding an
2 immunoglobulin light chain of any one of claims 39-50.
- 1 54. An expression vector comprising the nucleic acid of claim 51.
- 1 55. An expression vector comprising the nucleic acid of claim 52.
- 1 56. The expression vector of claim 54, further comprising the nucleic acid of claim 51.
- 1 57. A host cell comprising the expression vector of claim 53.
- 1 58. A host cell comprising the expression vector of claim 54.
- 1 59. A host cell comprising the expression vector of claim 55.
- 1 60. The host cell of claim 57, further comprising the expression vector of claim 53.
- 1 61. A method of producing a polypeptide comprising an immunoglobulin heavy chain or an
2 immunoglobulin light chain, the method comprising:
3 (a) growing the host cell of claim 56 or 57 under conditions so that the host cell
4 expresses the polypeptide comprising the immunoglobulin heavy chain or the
5 immunoglobulin light chain; and
6 (b) purifying the polypeptide comprising the immunoglobulin heavy chain or the
7 immunoglobulin light chain.
- 1 62. A method of producing an antibody that binds human Notch3 or an antigen binding
2 fragment of the antibody, the method comprising:
3 (a) growing the host cell of claim 58 or 59 under conditions so that the host cell
4 expresses a polypeptide comprising the immunoglobulin heavy chain and the

- 5 immunoglobulin light chain, thereby producing the antibody or the antigen-binding
6 fragment of the antibody; and
7 (b) purifying the antibody or the antigen-binding fragment of the antibody.

1 63. The antibody of any one of claims 1-4, 16-27, or 39-50, wherein the antibody has a K_D
2 of 15 nM or lower, as measured by surface plasmon resonance or bio-layer interferometry.

1 64. An isolated antibody that competes with the antibody of any one of claims 1-4, 16-27,
2 or 39-50 for binding to the extracellular domain of human Notch3.

1 65. An isolated antibody that competes with the antibody of any one of claims 1-4, 16-27,
2 or 39-50 for binding to EGF-like repeats 11-12 of human Notch3.

1 66. An isolated antibody that binds to the same epitope on human Notch3 as the antibody of
2 any one of claims 1-4, 16-27, or 39-50.

1 67. A method of inhibiting proliferation of a tumor cell comprising exposing the cell to an
2 effective amount of the antibody of any one of claims 1-4, 16-27, or 39-50 to inhibit
3 proliferation of the tumor cell.

1 68. A method of inhibiting tumor growth in a mammal, the method comprising exposing
2 the mammal to an effective amount of the antibody of any one of claims 1-4, 16-27, or 39-50 to
3 inhibit proliferation of the tumor.

1 69. A method of treating cancer in a mammal, the method comprising administering an
2 effective amount of the antibody of any one of claims 1-4, 16-27, or 39-50 to a mammal in
3 need thereof.

1 70. The method of claim 68, wherein the cancer is selected from the group consisting of
2 leukemia, breast cancer, lung cancer, pancreatic cancer, endometrial cancer, ovarian cancer,
3 prostate cancer, cervical cancer, brain cancer, skin cancer, colorectal cancer, gastric cancer,
4 head and neck cancer, and leukemia.

1 71. A method of inhibiting angiogenesis in mammal, the method comprising administering
2 an effective amount of the antibody of any one of claims 1-4, 16-27, or 39-50 to a mammal in
3 need thereof.

- 1 72. The method of any one of claims 67-70, wherein the mammal is a human.



FIG. 2

Human Notch3 ECD (amino acids 40-1643)

			<u>40</u>	<u>50</u>	<u>60</u>
			A	PPCLDGSPCA	NGGRCTQLPS
<u>70</u>	<u>80</u>	<u>90</u>	<u>100</u>	<u>110</u>	<u>120</u>
REAACLCP	PGWVGERCQ	LED PCHSGPC	AGR GVCQSSV	VAG TARFSCRC	PR GFRGPDC
<u>130</u>	<u>140</u>	<u>150</u>	<u>160</u>	<u>170</u>	<u>180</u>
DPCLSSPCA	H GARC	SVGPDG RFLCSC	PPGY QGRSC	RSVD ECRVGE	PCRH GGTCLN
<u>190</u>	<u>200</u>	<u>210</u>	<u>220</u>	<u>230</u>	<u>240</u>
FRCQCPAG	YT GPLCEN	PAVP CAPSP	CRNGG TCRQSG	DLTY DCACLP	GFEG QNCEVN
<u>250</u>	<u>260</u>	<u>270</u>	<u>280</u>	<u>290</u>	<u>300</u>
PGHRCLNG	GT CVDGVN	TYNC QCPPE	WTGQF CTEDV	DECQL QPNACH	NGGT CFNTLG
<u>310</u>	<u>320</u>	<u>330</u>	<u>340</u>	<u>350</u>	<u>360</u>
VCVNGWTG	ES CSQNID	DCAT AVCFH	GATCH DRVAS	FYCAC PMGKT	GLLCH LDDAC
<u>370</u>	<u>380</u>	<u>390</u>	<u>400</u>	<u>410</u>	<u>420</u>
HEDAICDT	NP VNGRAI	CTCP PGFTG	GACDQ DVDECS	IGAN PCEHL	GRCVN TQGSFL
<u>430</u>	<u>440</u>	<u>450</u>	<u>460</u>	<u>470</u>	<u>480</u>
RGYTGP	RCET DVNEC	LSGPC RNQAT	CLDRI GQFTC	ICMAG FTGTY	CEVDI DECQSS
<u>490</u>	<u>500</u>	<u>510</u>	<u>520</u>	<u>530</u>	<u>540</u>
GGVCKDR	VNG FSCTC	PSGFS GSTCQ	LDVDE CASTP	CRNGA KCVDQ	PDGYE CRCAE
<u>550</u>	<u>560</u>	<u>570</u>	<u>580</u>	<u>590</u>	<u>600</u>
LCDRNVDD	CS PDPCH	HGRCV DGIAS	FSCAC APGYT	GTRCE SQVDE	CRSQP CRHGG
<u>610</u>	<u>620</u>	<u>630</u>	<u>640</u>	<u>650</u>	<u>660</u>
VDKYL	CRCP	S GTTGVN	CEVN IDDCAS	NPCT FGVC	RDGINR YDCVC
					QPGFT GPLCN
					VEINE

FIG. 2 (cont.)

670	680	690	700	710	720
CASSPCGEGG	SCVDGENGFR	CLCPPGSLPP	LCLPPSHPCA	HEPCSHGICY	DAPGGFRCVC
730	740	750	760	770	780
EPGWSGPRCS	QSLARDACES	QPCRAGGTCS	SDGMGFHCTC	PPGVQGRQCE	LLSPCTPNPC
790	800	810	820	830	840
EHGGRCESAP	GQLPVCSCPQ	GWQGPRCQOD	VDECAGPAPC	GPHGICTNLA	GSFSCTCHGG
850	860	870	880	890	900
YTGPSCDQDI	NDCDPNPCLN	GGSCQDGVGS	FSCSCLPGFA	GPRCARDVDE	CLSNPCGPGT
910	920	930	940	950	960
CTDHVASFTC	TCPPGYGGFH	CEQDLPCDSC	SSCFNGGTCV	DGVNSFSLC	RPGYTGAHCQ
970	980	990	1000	1010	1020
HEADPCLSRP	CLHGGVCSAA	HPGFRCTCLE	SFTGPQCQTL	VDWCSRQPCQ	NGGRCVQTGA
1030	1040	1050	1060	1070	1080
YCLCPPGWSG	RLCDIRSLPC	REAAAQIGVR	LEQLCQAGGQ	CVDEDSSHYC	VCPEGRTGSH
1090	1100	1110	1120	1130	1140
CEQEVDPCLA	QPCQHGGTCR	GYMGGYMCEC	LPGYNGDNCE	DDVDECASQP	CQHGGSCIDL
1150	1160	1170	1180	1190	1200
VARYLCSCPP	GTLGVLCEIN	EDDCGPGPPL	DSGPRCLHNG	TCVDLVGGFR	CTCPPGYTGL
1210	1220	1230	1240	1250	1260
RCEADINECR	SGACHAAHTR	DCLQDPGGGF	RCLCHAGFSG	PRCQTVLSPC	ESQPCQHGGQ
1270	1280	1290	1300	1310	1320
CRPSPGPGGG	LTFTCHCAQP	FWGPRCERVA	RSCRELQCPV	GVPCQQTPRG	PRCACPPGLS
1330	1340	1350	1360	1370	1380
GPSCRSFPGS	PPGASNASCA	AAPCLHGGSC	RPAPLAPFFR	CACAQGWTPG	RCEAPAAAPE
1390	1400	1410	1420	1430	1440

FIG. 2 (cont.)

VSEEPKCPRA ACQAKRGDQR CDRECNSPGC GWDGGDCSLG VGDPRQCEA LQCWRLFNNL

1450 1460 1470 1480 1490 1500

RCDPACSSPA CLYDNFDCHA GGRERTCNPV YEKYCADHFA DGRCDQGCNT EECGWDGLDC

1510 1520 1530 1540 1550 1560

ASEVPALLAR GVLVLTVLLP PEELLRSSAD FLQRLSAILR TSLRFRLLAH GQAMVFPYHR

1570 1580 1590 1600 1610 1620

PSPGSEPRAR RELAPEVIGS VVMLEIDNRL CLQSPENDHC FPDAQSAADY LGALSAVERL

1630 1640

DFPYPLRDVR GEPLPEPEPS VPL (SEQ ID NO:19)

FIG. 3

Human Notch3 EGF-Like Repeats 1-11 (amino acids 40-467)

			<u>40</u>	<u>50</u>	<u>60</u>
			A PPCLDGSPCA NGGRCTQLPS		
<u>70</u>	<u>80</u>	<u>90</u>	<u>100</u>	<u>110</u>	<u>120</u>
REAACLCP	PGWVG	ERCQLED	PCHSGPCAGR	GVCQSSVVAG	TARFSCRCPR
					GFRGPD
					CSLP
<u>130</u>	<u>140</u>	<u>150</u>	<u>160</u>	<u>170</u>	<u>180</u>
DPCLSS	PCAH	GARCSV	GP	DPG	RFLCSCPPGY
					QGRSCRS
					DVD
					ECRVGE
					PCRH
					GGTCLN
					TPGS
<u>190</u>	<u>200</u>	<u>210</u>	<u>220</u>	<u>230</u>	<u>240</u>
FRCQCP	PAGYT	GPLCEN	PAVP	CAPSPCR	NNGG
					TCRQSG
					DLTY
					DCACLP
					GFEG
					QNCEVN
					VDDC
<u>250</u>	<u>260</u>	<u>270</u>	<u>280</u>	<u>290</u>	<u>300</u>
PGHRCL	NNGT	CVDGVN	TYNC	QCPPEW	TGQF
					CTEDV
					DECQL
					QPNACH
					NNGT
					CFNTL
					GGHSC
<u>310</u>	<u>320</u>	<u>330</u>	<u>340</u>	<u>350</u>	<u>360</u>
VCVNGW	TGES	CSQNID	DCAT	AVCFHG	ATCH
					DRVAS
					FYCAC
					PMGKT
					GLLCH
					LDDACV
					SNPC
<u>370</u>	<u>380</u>	<u>390</u>	<u>400</u>	<u>410</u>	<u>420</u>
HEDAIC	DTNP	VNGRAI	CTCP	PGFTGG	ACDQ
					DVDECS
					SIGAN
					PCEHL
					GRCVN
					TQGS
					FLCQCG
<u>430</u>	<u>440</u>	<u>450</u>	<u>460</u>		
RGYTGP	RCET	DVNECL	SGPC	RNQATC	LDRI
					GQFTC
					CICMAG
					FTGTYCE

(SEQ ID NO: 20)

FIG. 4

evqllesggglvqpqgslrlscaasgftfs

dymms

wvrqapgkglewv
CDR_{H1}

s

wirssggttlyadsvkg

rftisrdnskntlylqmnsdraedtatyyc
CDR_{H2}

ar

vsggttgyafdi

wgqgtmvtvss (SEQ ID NO: 6)
CDR_{H3}

Heavy Chain Variable Region of Antibody 28042

FIG. 5

diqmtqspsslsasvgdrvtitc[rasqsisnyln]wyqqkpgka

CDR_{L1}

pklliy[gasslqs]gvpsrvsgtgsgtdftltisslqpedfaty

CDR_{L2}

yc[qqsyspsft]fgpgtkvdf (SEQ ID NO:10)

CDR_{L3}

Kappa Chain Variable Region of Antibody 28042




FIG. 6




FIG. 7

FIG. 8




FIG. 9

Notch3 ICD Cleavage Assay
in NCI-H838

NCI-H838


WB: α -Notch3 (Cell Signaling, #3446)

FIG. 10A




FIG. 10B





FIG. 11

Notch3 Luciferase Reporter Assay



	28042	ABX	hFC
Bottom	5.274	-5.460	
Top	78.55	~324.2	
LogIC50	-0.2759	~4.539	
HillSlope	0.8265	0.1993	
IC50	0.5298	~34588	
Span	73.28	~329.7	

	28042	ABX	hFC
R square	0.9861	0.9767	

FIG. 12A





FIG. 12B



28042	diqmtqspsslsasvqdrvtitc	rasqsisnyln	wyqakpgkapklliy	gasslqs
28042.1 N31S	diqmtqspsslsasvqdrvtitc	rasqsisnyln	wyqakpgkapklliy	gasslqs
28042.2 G50A	diqmtqspsslsasvqdrvtitc	rasqsisnyln	wyqakpgkapklliy	gasslqs
28042.3 F106I	diqmtqspsslsasvqdrvtitc	rasqsisnyln	wyqakpgkapklliy	gasslqs
28042.4 E107K	diqmtqspsslsasvqdrvtitc	rasqsisnyln	wyqakpgkapklliy	gasslqs
28042.5 N31S, G50A	diqmtqspsslsasvqdrvtitc	rasqsisnyln	wyqakpgkapklliy	gasslqs
28042.6 F106I, E107K	diqmtqspsslsasvqdrvtitc	rasqsisnyln	wyqakpgkapklliy	gasslqs
28042.7 N31S, G50A, F106I, E107K	diqmtqspsslsasvqdrvtitc	rasqsisnyln	wyqakpgkapklliy	gasslqs
28042.8 V62F	diqmtqspsslsasvqdrvtitc	rasqsisnyln	wyqakpgkapklliy	gasslqs
28042.9 T65S	diqmtqspsslsasvqdrvtitc	rasqsisnyln	wyqakpgkapklliy	gasslqs
28042.10 N31S, G50A, V62F, T65S	diqmtqspsslsasvqdrvtitc	rasqsisnyln	wyqakpgkapklliy	gasslqs
		CDR _{L1}		
28042	gvpsrvsgsgtdftltisslqpedfatyycc	qqsyspsft	fgpgtkvdfe	(SEQ ID NO:10)
28042.1 N31S	gvpsrvsgsgtdftltisslqpedfatyycc	qqsyspsft	fgpgtkvdfe	(SEQ ID NO:23)
28042.2 G50A	gvpsrvsgsgtdftltisslqpedfatyycc	qqsyspsft	fgpgtkvdfe	(SEQ ID NO:24)
28042.3 F106I	gvpsrvsgsgtdftltisslqpedfatyycc	qqsyspsft	fgpgtkvdfe	(SEQ ID NO:25)
28042.4 E107K	gvpsrvsgsgtdftltisslqpedfatyycc	qqsyspsft	fgpgtkvdIK	(SEQ ID NO:26)
28042.5 N31S, G50A	gvpsrvsgsgtdftltisslqpedfatyycc	qqsyspsft	fgpgtkvdfe	(SEQ ID NO:27)
28042.6 F106I, E107K	gvpsrvsgsgtdftltisslqpedfatyycc	qqsyspsft	fgpgtkvdIK	(SEQ ID NO:28)
28042.7 N31S, G50A, F106I, E107K	gvpsrvsgsgtdftltisslqpedfatyycc	qqsyspsft	fgpgtkvdIK	(SEQ ID NO:29)
28042.8 V62F	gvpsrFsgtsgtdftltisslqpedfatyycc	qqsyspsft	fgpgtkvdfe	(SEQ ID NO:40)
28042.9 T65S	gvpsrvsgsgtdftltisslqpedfatyycc	qqsyspsft	fgpgtkvdfe	(SEQ ID NO:41)
28042.10 N31S, G50A, V62F, T65S	gvpsrFsgsgtdftltisslqpedfatyycc	qqsyspsft	fgpgtkvdfe	(SEQ ID NO:42)
		CDR _{L3}		

Complete Light (Kappa) Chain Variable Region Amino Acid Sequence Alignments

FIG. 13

28042	rasqsisnyln	(SEQ ID NO:7)	gasslqs	(SEQ ID NO:8)
28042.1 N31S	rasqsisSyln	(SEQ ID NO:21)	gasslqs	(SEQ ID NO:8)
28042.2 G50A	rasqsisnyln	(SEQ ID NO:7)	gasslqs	(SEQ ID NO:22)
28042.3 F106I	rasqsisnyln	(SEQ ID NO:7)	gasslqs	(SEQ ID NO:8)
28042.4 E107K	rasqsisnyln	(SEQ ID NO:7)	gasslqs	(SEQ ID NO:8)
28042.5 N31S, G50A	rasqsisSyln	(SEQ ID NO:21)	gasslqs	(SEQ ID NO:22)
28042.6 F106I, E107K	rasqsisnyln	(SEQ ID NO:7)	gasslqs	(SEQ ID NO:8)
28042.7 N31S, G50A, F106I, E107K	rasqsisSyln	(SEQ ID NO:21)	gasslqs	(SEQ ID NO:22)
28042.8 V62F	rasqsisnyln	(SEQ ID NO:7)	gasslqs	(SEQ ID NO:8)
28042.9 T65S	rasqsisnyln	(SEQ ID NO:7)	gasslqs	(SEQ ID NO:8)
28042.10 N31S, G50A, V62F, T65S	rasqsisSyln	(SEQ ID NO:21)	gasslqs	(SEQ ID NO:22)
	CDR _{L1}			
28042	qqsypspsft	(SEQ ID NO:9)		
28042.1 N31S	qqsypspsft	(SEQ ID NO:9)		
28042.2 G50A	qqsypspsft	(SEQ ID NO:9)		
28042.3 F106I	qqsypspsft	(SEQ ID NO:9)		
28042.4 E107K	qqsypspsft	(SEQ ID NO:9)		
28042.5 N31S, G50A	qqsypspsft	(SEQ ID NO:9)		
28042.6 F106I, E107K	qqsypspsft	(SEQ ID NO:9)		
28042.7 N31S, G50A, F106I, E107K	qqsypspsft	(SEQ ID NO:9)		
28042.8 V62F	qqsypspsft	(SEQ ID NO:9)		
28042.9 T65S	qqsypspsft	(SEQ ID NO:9)		
28042.10 N31S, G50A, V62F, T65S	qqsypspsft	(SEQ ID NO:9)		
	CDR _{L3}			

Light (Kappa) Chain CDR Amino Acid Alignments

FIG. 14

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/030156

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/00 A61P35/00 C07K16/28
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61P A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2014/159239 A2 (NOVARTIS AG [CH]; DEPLAZES-LAUBER JOELLE [DE]; FRYER CHRISTY [US]; HU) 2 October 2014 (2014-10-02) page 158, lines 4-6; figures 13-19 -----	1-72
X	WO 2014/100435 A1 (AVEO PHARMACEUTICALS INC [US]) 26 June 2014 (2014-06-26) examples 1-13 ----- -/--	1-72



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

31 August 2017

Date of mailing of the international search report

08/09/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Cilensek, Zoran

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2017/030156

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LI KANG ET AL: "Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 283, no. 12, 21 March 2008 (2008-03-21), pages 8046-8054, XP002481515, ISSN: 0021-9258, DOI: 10.1074/JBC.M800170200 the whole document	1-72
A	RONNY FALK ET AL: "Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cells", METHODS, vol. 58, no. 1, 1 September 2012 (2012-09-01), pages 69-78, XP055194367, ISSN: 1046-2023, DOI: 10.1016/j.ymeth.2012.07.008 the whole document	1-72
A	LIN LUPING ET AL: "Targeting Specific Regions of the Notch3 Ligand-Binding Domain Induces Apoptosis and Inhibits Tumor Growth in Lung Cancer", CANCER RESEARCH, AACR - AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 70, no. 2, 15 January 2010 (2010-01-15), pages 632-638, XP009137926, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-09-3293 [retrieved on 2010-01-12] the whole document	1-72
A	KITTICHOAT TIYANONT ET AL: "Insights into Notch3 Activation and Inhibition Mediated by Antibodies Directed against Its Negative Regulatory Region", JOURNAL OF MOLECULAR BIOLOGY, vol. 425, no. 17, 1 September 2013 (2013-09-01), pages 3192-3204, XP055402468, United Kingdom ISSN: 0022-2836, DOI: 10.1016/j.jmb.2013.05.025 the whole document	1-72

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2017/030156

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
- a. ☐ forming part of the international application as filed:
- ☐ in the form of an Annex C/ST.25 text file.
- ☐ on paper or in the form of an image file.
- b. ☐ furnished together with the international application under PCT Rule 13~~ter~~.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
- c. ☒ furnished subsequent to the international filing date for the purposes of international search only:
- ☒ in the form of an Annex C/ST.25 text file (Rule 13~~ter~~.1(a)).
- ☐ on paper or in the form of an image file (Rule 13~~ter~~.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/030156

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2014159239 A2	02-10-2014	CN 105246916 A	13-01-2016
		EP 2970479 A2	20-01-2016
		JP 2016514130 A	19-05-2016
		WO 2014159239 A2	02-10-2014

WO 2014100435 A1	26-06-2014	EP 2935330 A1	28-10-2015
		US 2016185852 A1	30-06-2016
		WO 2014100435 A1	26-06-2014
